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Ischemic heart disease is the leading cause of death in the western society and a major 
health problem in developing countries. In the current study, the role of hydrogen 
sulfide (H2S) in the cardioprotection against ischemic heart injury was investigated. 
Firstly, the role of H2S in excitation-contraction coupling in cardiomyocytes was 
studied. H2S was shown to negatively modulate the β-adrenergic system, which is over-
stimulated during ischemia/reperfusion, via inhibiting adenyly cyclase activity. This 
inhibition resulted in reduced cAMP production, and thus may prevent calcium 
overload-induced ventricular arrhythmias. Further experiments were conducted to 
confirm the cardioprotective effects of H2S in isolated rat heart and cardiomyocytes. 
Endogenous H2S production in heart was found to be suppressed in cardiomyocytes 
subjected to ischemia. Preconditioning or postconditioning the hearts with several 
episodes of brief ischemia significantly restored the H2S production in the heart 
accompanied by improved heart contractile function during reperfusion. Inhibition of 
H2S synthesis partially blocked the cardioprotective effect of both pre- and post-
conditioning, indicating that endogenous H2S may, at least in part, mediate the 
protection given rise by these two maneuvers. The present study also demonstrated that 
NaHS, an H2S donor, was an effective pharmacological pre- and post-conditioning 
agent to ameliorate the cardiac injury induced by ischemia/reperfusion (I/R) in terms of 
cells death, cell morphology, intracellular calcium handling, cellular and heart 
contractile function, infarction size, and arrhythmias.  
 The interaction between H2S and nitric oxide (NO), two important 
gasotransmitters, was also studied in this thesis. Mixture of NaHS with different NO 
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donors and L-arginine, a main substrate for NO synthase to generate NO, exerted 
completely opposite effects on myocytes contractile function and calcium cycling, 
suggesting that a novel reaction product of H2S +NO, may be formed. Additional 
experiments demonstrated that this novel compound may be nitroxyl since this novel 
substance possesses several properties very similar to that of nitroxyl, like producing 
positive inotropic effect via cAMP/PKA, cGMP/PKG independent pathways, in which 
their effects were sensitive to thiols.   
 In conclusion, H2S may negatively modulate the β-adrenergic system which 
translates H2S into a good cardioprotective agent to protect the heart from 
ischemia/reperfusion injury, when the β-adrenergic receptor is over-stimulated. In 
addition, the present study also demonstrated that H2S may sophisticatedly regulate 
excitation-contraction coupling in the heart by modulating intracellular calcium in a 
totally different manner in the presence of NO, suggesting the formation of a novel 
compound, which potentially plays a significant role during certain conditions like 
inflammation, when both gasotransmitters are highly produced.    
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Chapter 1  Introduction 
1.1. General Overview 
The cardiovascular system consists of the heart and blood vessels which provides the 
tissues/organs of the body with a continuous supply of oxygen, nutrients, and waste 
removal. The heart is the first organ formed during embryonic development and is 
responsible for circulating approximately 7200 liters of blood per day throughout the 
vasculature of a human adult. The mammalian heart is comprised of four chambers, two 
atria and two ventricles operating in a series of electrical and mechanical events that 
control blood flow into and out of the heart. A region of the heart called the sinoatrial 
(SA) node is capable of producing and discharging an action potential and sending the 
impulse across the atria to cause both left and right atria to contract in unison. The 
impulses then pass to the atrioventricular (AV) node, and the signal is further conducted 
by a specialized muscle fiber, Purkinje fibers, to the apex of the heart and throughout 
the ventricular walls. The impulses generated during the heart cycle produce small 
electrical currents, which are conducted through body fluids to the skin, where they can 
be detected by electrodes and recorded as an electrocardiogram (ECG). Over the past 
100 years, contractile functions of the heart have been extensively studied, and we now 
understand the basic mechanisms of heart contraction and relaxation.  
1.2. Excitation-contraction coupling 
In adult mammalian hearts, excitation-contraction coupling, the key determinant of 
cardiac function, is the process from electrical excitation to contraction of the myocyte 
(Bers, 2002; Fabiato and Fabiato, 1977).  During a cardiac action potential, upon the 
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depolarization of sarcolemma, Ca2+ enters the cell through L-type Ca2+ channel, as an 
inward Ca2+ current (ICa), which activates the sarcoplasmic reticulum (SR) Ca2+ release 
channel, ryanodine receptor (RyR2), triggering Ca2+ release from the SR. This process 
is termed as Ca2+-induced Ca2+ release (Bers, 2002). The combination of Ca2+ influx 
and release raises the free intracellular Ca2+ concentration ([Ca2+]i) from 150nM to 
1µM, allowing Ca2+ to bind to the myofilament protein troponin C, which then initiates 
contraction (Bers, 2002). For relaxation to occur, Ca2+ must be removed from the 
cytosol, allowing Ca2+ to dissociate from troponin C (Solaro and Rarick, 1998). Four 
separate Ca2+ handling systems participate in the removal of Ca2+: 1) SR Ca2+-ATPase 
(SERCA2a), 2) sarcolemmal Na+-Ca2+ exchanger (NCX), 3) sarcolemmal Ca2+-ATPase 
and 4) mitochondrial Ca2+ uniport (Bassani et al., 1994; Bers, 2002; Lederer et al., 
1990; Shannon and Bers, 2004). Although the contribution of NCX and SERCA2a to 
Ca2+ decline is species-dependent, the sarcolemmal Ca2+-ATPase and mitochondrial 
Ca2+ uniport generally play a minor role in the Ca2+ decline (~ 1-2% of the Ca2+) during 
relaxation (Bassani et al., 1992; Bers et al., 1993).  
1.2.1. Intracellular calcium cycling in adult mammalian hearts 
In adult mammalian hearts, SR Ca2+ cycling plays a key role in the intracellular Ca2+ 
homeostasis and the regulation of cardiac function (Fabiato and Fabiato, 1977; Lederer 
et al., 1990). The SR Ca2+ release during each cardiac cycle is the determinant of the 
force generated and the SERCA2a Ca uptake plays a central role in controlling the SR 
Ca2+ load and cardiac relaxation (Baker et al., 1998; Luo et al., 1994). However, the 
trans-sarcolemma Ca2+ cycling systems, i.e. L-type Ca2+ channel and NCX, are also 
important for the regulation of intracellular Ca2+ cycling and excitation-contraction 
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coupling. Specifically, to maintain intracellular Ca2+ homeostasis and normal cardiac 
function, the Ca2+ efflux via NCX must be matched by the Ca2+ influx from L-type Ca2+ 
channel (Haddock et al., 1998). The Ca2+ release from SR must be equal to SERCA2a 
Ca2+ re-uptake during each steady-state heartbeat (Shannon and Bers, 2004). Thus, the 
regulation of each system is critical for normal cardiac contractile function on a beat-to-





Figure 1-1  Calcium transport in ventricular myocytes. Inset shows the time course of an action potential, 
calcium transient and contraction measured in a rabbit ventricular myocytes at 37˚C. NCX, Na+/Ca2+ exchanger; 
ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic reticulum.  
This figure is obtained from Bers (2002) (Bers, 2002) 
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1.2.1.1. Voltage-dependent L-type Ca2+ channel  
The core cardiac L-type voltage-dependent Ca2+ channel is heterotetrameric polypeptide 
complex composed of α1c subunit, the transmembrane α2/δ subunit and the cytoplasmic  
β subunit located within transverse tubule network. A propragating action potential 
down the transverse-tubules activate the voltage-sensitive α1 subunit Ca2+ pore 
facilitating extracellular Ca2+ entry, whereas  α2/δ and  β subunits are auxillary 
components in this process (Gurnett and Campbell, 1996).  The L-type Ca2+ channel is 
the link between electrical excitation and mechanical contraction in the cardiomyocyte 
by initiating the first step in Ca2+ mobilization. In cardiomyocytes, this channel is the 
main port for Ca2+ entry controlling intracellular Ca2+ concentration, ultimately 
determining the strength of contraction. This important role explains the convergence of 
multiple signalling cascades regulating the activity of the L-type Ca2+ channel protein.  
Single channel and whole cell patch-clamp analysis demonstrated Ca2+ inward 
amplitude can be increased by several phosphorylating kinases: PKA, PKC cGMP-
dependent kinase, and calmodulin kinase II (Mori et al., 1996; Muth et al., 1999). 
Enhancing Ca2+ entry elicits an increasing SR Ca2+ release, generating a graded 
contractile response in cardiomyocytes. Increase of Ca2+ entry  augments existing 
cytosolic and SR Ca2+ stores, inducing stronger contraction within the sarcomeric 
machinery in subsequent rounds of excitation-contraction coupling  (Houser et al., 
2000). SR Ca2+ release increases regional Ca2+ concentration surrounding the L-type 
Ca2+ channel, which in turn induces Ca2+-dependent inactivation of the L-type Ca2+ 
channel by closing the gating mechanism within the α1c-subunit. Slower or reduced SR 
Ca2+ release decreases the rate of inactivation of the channel.   
  
5
1.2.1.2. Ryanodine receptor 
The ryanodine receptor, or Ca2+ release channel, was initially characterized as a ~565 
kDa protein (Otsu et al., 1990) that forms homotetramers (~2.2 MDa) on the junctional 
sarcoplasmic membrane. Each subunit contains a large cytosolic domain and a smaller 
intra-membrane domain surrounding a Ca2+-specific central pore perforating the 
sarcoplasmic reticulum membrane. Mammalian tissues express three receptor isoforms: 
RyR1, skeletal muscle; RyR2, cardiac muscle; and RyR3, brain tissue (Hamilton and 
Serysheva, 2009). Cardiac RyR2 is functionally unique from skeletal RyR1 in that SR 
Ca2+ release is induced by Ca2+ and is not mechanically coupled to L-type Ca2+ channels 
as in skeletal muscle (Fabiato and Fabiato, 1978). In this context, cardiac SR Ca2+ 
release is a graded response depends on the amount of calcium influx through L-type 
Ca2+ channel, which is critical for cardiac reserve and variable force generation in 
cardiomyocytes. Recent reports documented that L-type Ca2+ channels and RyR2 
receptors form functional clusters in the space between the sarcolemmal and SR 
membranes in cardiac cells (MacLennan et al., 2002).  Indeed, functional activation of 
single or multiple groups of these clusters give rise to a “Ca2+ spark” which can be 
visualized by Ca2+ sensitive dyes in isolated cardiomyocytes (Cheng et al., 1993).  
RyR2 function is regulated by activating agonists such as low concentrations of 
ryanodine and calmodulin, caffeine, and ATP in the presence of Ca2+ (Ikemoto et al., 
1995; Meissner and Henderson, 1987; Rousseau and Meissner, 1989; Smith et al., 1988; 
Tripathy et al., 1995), causing conformational rotation of the tertiary complex to the 
open position and allowing Ca2+ flow from the SR. Additionally, high luminal SR Ca2+ 
concentration enhances the open probability of the RyR2, whereas low Ca2+ 
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concentration tends to reduce this activity (Fill and Copello, 2002). Recent reports show 
that hyperphosphorylation of the RyR2 channel and associated  proteins may affect SR 
Ca2+ loading by increasing the open probability of the channel (Marx et al., 2000), 
however, this concept is not universally accepted (Jiang et al., 2002; Li et al., 2002) , 
which suggests SR Ca2+ content is primarily dependent on the activity of SERCA 
protein.   
1.2.1.3. Sarcoplasmic reticulum Ca2+ ATPase  
SERCA2a is the primary Ca2+ transporter in the heart, utilizing the energy from ATP 
hydrolysis to relocate Ca2+ ions against a ~1000-fold concentration gradient into the SR 
lumen (Hasselbach and Oetliker, 1983). Active Ca2+ transport is accomplished through 
small energetically-favorable steps dependent on cytosolic Ca2+ and ATP levels (Katz, 
2001). Kinetically, SERCA2 activity is directly regulated by phosopholamban (Luo et 
al., 1994). Dephosphorylated phospholamban binds to SERCA2 in a monomeric 
conformation, inhibits rate-limiting steps in enzymatic reaction kinetics (Katz, 2001) for 
Ca2+ reuptake, slows down SR Ca2+ loading and affects sarcomeric relaxation. 
Phosphorylation of phospholamban by PKA (Tada et al., 1983) and  CamKII  (Kranias 
et al., 1980) turns phospholamban into a pentameric form, thereby releasing SERCA2 
inhibition and increasing SR Ca2+ uptake and ATPase activity (Tada et al., 1982). 
Cardiac-specific ablation of phospholamban, which increases SR Ca2+ loading, is 
accompanied by accelerated muscle relaxation in knockout mice. (Bluhm et al., 2000) 
Conversely, overexpression of phospholamban significantly inhibits SERCA activity, 
and affects Ca2+ cycling which leads to cardiomyopathy (Dash et al., 2001) in 
transgenic mice.   
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Dependence on SERCA2 for cytosolic Ca2+ uptake varies among species. Mice 
and rats predominantly rely on SERCA2 (~90%) for diastolic relaxation. Dependency 
shifts to ~70% in larger animals including humans (Bers, 2002), delegating the 
remainder of Ca2+ uptake to the NCX (~28%) and slow sarcolemmal Ca2+ ATPases 
(~1%) (Bers, 2002). Regardless of species, SERCA2 remains as the predominating 
protein responsible for SR Ca2+ loading and relaxation in cardiomyocytes.   
1.2.1.4. Na+-Ca2+ Exchanger  
The NCX catalyzes exchange of three Na+ ions (influx) for one Ca2+ ion (efflux) 
creating an electrogenic gradient across the plasma membrane (Shigekawa and 
Iwamoto, 2001). Recent studies demonstrated that the mature cardiac NCX1 isoform 
(~120 kDa) can functionally operate in two modes, forward and reverse (Bers, 2002). 
Depending on the electrical activity of the cardiomyocyte, Ca2+ is extruded (forward 
mode) or entered (reverse mode) the myocyte. Although the capacity of the  reverse 
mode on excitation-contraction coupling remains controversial (Bers, 2002), it is widely 
accepted that forward mode plays a supplementary role in diastolic relaxation.  
Overexpression of NCX1 protein in transgenic mice was shown to enhance Ca2+ 
transient recovery and myocyte contractility (Yao et al., 1998). In contrast, adenovirally 
infected rabbit myocytes overexpressing NCX showed abnormal contractility and Ca2+ 
handling, illustrating the disparity between human and rodent dependency on this 
molecule (Ranu et al., 2002).  
Unlike SERCA2, L-type Ca2+ channel, and RyR2 which are regionally localized, 
NCX is spatially arranged throughout the sarcolemmal membrane and  intercalated 
disks (Shigekawa and Iwamoto, 2001) returning Ca2+ to the extracellular space and 
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counterbalancing Ca2+ entry via the L-type Ca2+ channel.  NCX activity is affected by 
intracelluar and extracellular Na+ and Ca2+ concentrations. Interestingly, removing 
extracellular Na+ and Ca2+ ions in buffer solutions surrounding isolated cardiomyocytes 
inhibits forward mode exchanger activity, preventing Ca2+ extrusion during diastole 
(Yao et al., 1998). Receptor mediated stimulation by PKC and possibly PKA signaling 
cascades result in activation of NCX which in turn enhances forward mode Ca2+ 
extrusion. However, the precise mechanisms by which these changes occur on NCX 
protein remain controversial (Shigekawa and Iwamoto, 2001). 
1.2.2. β-adrenergic signaling 
1.2.2.1. Effect of β-adrenergic signaling on Ca2+ cycling and cardiac function  
The sympathetic nervous system is characteristically responsible for the “flight” or 
stress response program in mammals. With regards to the heart, the β-adrenergic 
signalling pathway is the primary mechanism that transiently increases cardiac output. 
The β-adrenergic receptors are transducers which link hormone-mediated chemical 
signals to the mechanical event of augmented myocardial contraction. Of the three 
known β-receptor isoforms (β1, β2 and β3), β1- and β2-receptors primarily transduce 
neurohormonal input into the myocyte, with β1-receptor as the major subtype (~70-
80%) (Dorian, 2005). In cellular level, the classic route of contractile function 
stimulation is the result of the activation of adenylyl cyclase (AC) catalytic activity by 
the β-adrenoceptor-coupled stimulatory G protein, which leads to increased intracellular 
cAMP level. This in turn stimulates protein kinase A (PKA) which then mediates 
phosphorylation of L-type Ca2+ channels leading to Ca2+ influx to the intracellular 
compartment. Ca2+ entry triggers Ca2+ release from sarcoplasmic reticulum and the 
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elevated free intracellular Ca2+ ([Ca2+]i) bind to the myofilament protein troponin C, 
which then switch on the contractile machinery (Bers, 2002). In addition, activation of 
PKA also directly phosphorylates RyR2 and PLB. The former increases the open 
probability of RyR2 in SR (Takasago et al., 1989), whereas the latter stimulates SR-
Ca2+ uptake (Simmerman and Jones, 1998). Troponin I is an inhibitory protein 
associated with troponin C and T complex on tropomyosin (Bers, 2002). Enhanced 
phosphorylation of troponin I decreases troponin C affinity for Ca2+, which results in 
faster relaxation of the sarcomere (Bers, 2002). Collectively, these changes increase the 
Ca2+ transient amplitude, decrease diastolic relaxation time, and increase force 
generation of the myocyte, ultimately increasing cardiac output.  
 
Figure 1-2 β-adrenergic receptor activation and phosphorylation targets relevant to excitation-contraction 
coupling. Inset shows the time course of an action potential, calcium transient and contraction measured in a rabbit 
ventricular myocytes at 37˚C. NCX, Na+/Ca2+ exchanger; ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic 
reticulum.  
This figure is obtained from Bers (2002) (Bers, 2002) 
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1.2.2.2. β-adrenergic signaling and cardiac arrhythmias 
β1-stimulation leads to increased heart rate via stimulation of the If pacemaker current, 
which leads to spontaneous diastolic depolarization (Dorian, 2005). Heart rate is the key 
determinant of myocardial oxygen consumption and increased of heart rate (Habib, 
1997), a phenomenon termed as tachycardia, substantially increases myocardial oxygen 
demand. Accordingly, clinical evidence suggests a strong association between increased 
heart rate and cardiovascular mortality in the acute (Reich et al., 2002) and chronic 
setting (Cook et al., 2006). Myocardial ischemia may occur if oxygen consumption 
outstrips demand, and lead to multiple secondary electrophysiologic changes that are 
known to be arrhythmogenic (Thomas et al., 2004). It was also shown that during 
ischemia, accumulation of catecholamines within the extracellular space of myocardium 
enhanced the stimulation of sympathetic nervous system (Schomig et al., 1984). This 
may in turn result in intracellular calcium overload and hence delayed 
afterdepolorizations (DAD), triggering the occurrence of cardiac arrhythmia (Eisner et 
al., 2009). 
1.2.2.3. Calcium overload and arrhythmogenic calcium waves 
The term ‘Ca2+ overload’ is applied to conditions in which Ca2+ waves and their 
consequences (DAD and aftercontractions) are observed (Venetucci et al., 2008). Much 
research has elucidated how Ca2+ overload and waves develop. The first stage is an 
increase in Ca2+ loading of the SR, which can arise because of increased loading of the 
cell with Ca2+ as a consequence of an imbalance between Ca2+ entry and 
efflux.(Trafford et al., 2001; Trafford et al., 1997) This will result in an increase of SR 
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Ca2+ content until a threshold level is reached at which waves are observed (Venetucci 
et al., 2007). It appears that the increased SR Ca2+ content results in an increased 
frequency of Ca2+ sparks and hence in the Ca2+ wave initiation (Cheng et al., 1996). 
 For a Ca2+ wave to occur, the Ca2+ released from a point in the SR must be able 
to diffuse through the cytoplasm and trigger another release from other region 
(MacQuaide et al., 2007). It has been suggested that the Ca2+ released by a single spark 
will be taken up by cytoplasmic buffers and therefore unable to activate further release. 
Once the wave has been initiated, the greater the SR Ca2+ content, the greater the 
amount released and the more likely a wave is propagated (Cheng et al., 1996). The SR 
Ca2+ threshold can be decreased or increased by enhanced or inhibited open probability 
respectively (Trafford et al., 2000). Diastolic Ca2+ waves are thought to underlie certain 
forms of arrhythmia as a result of some of the calcium in the wave being pumped out of 
the cell by NCX (Venetucci et al., 2008). The resultant NCX current may depolarize the 
cell and result in a DAD (Venetucci et al., 2008). 
In summary, when SR Ca2+ content exceeds the critical SR threshold, Ca2+ wave 
is formed even in an unstimulated condition. This spontaneous Ca2+ release may then 
produce DADs and result in an action potential which causes ectopic beats and hence 
arrhythmias. As such, removal of Ca2+ overload is seen to be an important therapeutic 




1.3. Ischemic Heart Disease 
The 20th century saw significant increases in life expectancy and a major shift in the 
causes of illness and death throughout the world. During this transition, cardiovascular 
disease (CVD) became one of the most common causes of death worldwide. Before 
1900, infectious diseases and malnutrition were the most common causes of death in the 
world. With improved nutrition and public health measures, both have declined 
significantly. Increased longevity and the impact of smoking, unhealthy diets, and other 
risk factors have combined to make CVD and cancer the leading causes of death in 
most countries, including Singapore. Today, it accounts for nearly 30% of deaths 
worldwide including about 40% in high-income countries and approximately 28% in 
middle- and low-income nations (Libby et al, 2008).  
Cardiovascular disease covers wide array of disorders, such as disease of the 
cardiac muscle and of the vascular system supplying essential substances to heart, brain 
and other vital organs. The most common manifestations of CVD are coronary heart 
disease, congestive heart failure and stroke (Lopez et al, 2006).  
1.3.1. Epidemiology 
Ischemic heart disease, also called coronary heart disease, is one of the most common 
fatal diseases in the industrialized countries. In the United States, for instance, an 
estimated 17,600,000 American adults are living with ischemic heart disease (American 
Heart Association, 2010). This year, an estimated 785,000 people will suffer a new 
coronary attack and about 470,000 will have a recurrent coronary attack. The 
importance of coronary heart disease extends beyond the high morbidity and mortality 
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rates. Clinical manifestations are unpredictable or absent; and in 30~50% of patients, 
death is sudden and unexpected. The recognition of coronary heart decrease in any of its 
clinical forms raises the possibility of sudden death (Cheitlin et al., 1993).  
1.3.2. Ischemia-reperfusion injury 
Myocardial ischemia occurs when an atherosclerotic plaque that slowly builds up in the 
lumen of a coronary artery suddenly ruptures and blocks the blood flow downstream. 
Upon the obstruction, downstream myocardium is starved of oxygen and nutrients, 
where myocardial infarction (MI) develops (Reimer and Ideker, 1987). MI is a common 
presentation of ischemic heart disease. Most individuals with coronary heart disease 
show no evidence of narrowed artery for decades until the disease progresses to the 
advanced state when the first symptom, often a "sudden" heart attack, finally arise 
(American Heart Association, 2010).  
The myocardium can tolerate short-term (up to 15 minutes) of  myocardial 
ischemia without resulting cardiomyocytes death (Buja, 1998). During this short term 
ischemia episode, the defense mechanisms of heart seek to remedy this imbalance by 
decreasing myocardial contractile function and increasing the rate of glycolysis. 
(Braunwald and Kloner, 1982). Consequently, intracellular acidosis, resulted from the 
accumulation of glycolytic breakdown products, causes further inhibition of the 
contractile machinery (Heyndrickx et al., 1975). This phenomenon known as 
myocardial stunning, which is characterized by post-ischemic impairment of myocardial 
function, is considered acute and essentially reversible (Kloner and Jennings, 2001). 
With increasing duration of ischemia, greater irreversible myocardial damage could 
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develop upon a re-established blood flow to the blocked heart area, termed reperfusion 
injury (Yellon and Baxter, 2000). 
Ischemic injury is a very complex process involving the action and interaction of 
many factors. Intensive investigation over decades has provided a detailed 
understanding of the complexity of the response of myocardium to an ischemic insult. 
Within ten seconds of blood flow interruption to the heart, mitochondrial oxidative 
phosphorylation rapidly stops, resulting in depletion of high-energy phosphate 
compounds, including ATP and creatine phosphate (Hearse, 1979). As a compensatory 
effect, anaerobic glycolysis increases to produce ATP but also leads to the accumulation 
of hydrogen ions and lactate (Buja, 2005). The resultant intracellular acidosis causes 
alterations in ion transport in the sarcolemma and organellar membranes (Buja et al., 
1988; Thandroyen et al., 1992). Initially, there is increased K+ efflux related to an 
increased osmotic load caused by the accumulation of metabolites and inorganic 
phosphate. With a significant decline in ATP, the Na+, K+-ATPase is inhibited, resulting 
in a further decrease of K+ and an increase in Na+. In addition, intracellular acidosis also 
activates the sarcolemmal Na+–H+ antiport (Karmazyn, 1999; Yellon and Baxter, 2000), 
which facilitates proton extrusion in exchange for Na+. Collectively, this accumulated 
Na+ in turn causes Na+– Ca2+ exchanger to work in reverse mode, resulting in extrusion 
of Na+ which brings in Ca2+ (White et al., 1984). The resultant cytosolic loading of Ca2+ 
not only induces sustained impairment on contractile function, but also mediates the 
damage on cell membrane, which leads to the progression of the injury to an advanced 
stage (Buja, 2005).  
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Ischemia also causes the depletion of glutathione (GSH), which is very important in 
maintaining cellular protein and lipid structure and functions by protecting these 
molecules from oxidation (Ji, 2002). Due to depletion of GSH, the toxic effects of 
oxidative stress are exacerbated (Patterson and Rhoades, 1988). The oxidative stress 
caused by ischemia result in an increased production and/or decreased degradation of 
reactive oxygen species (ROS), consisting of superoxide anion, hydrogen peroxide and 
hydroxyl radical, which are harmful metabolic by-products (Chang and Wu, 2006). 
ROS may initiate a chain reaction that results in irreversible changes in proteins or 
lipids. In the heart, ROS are also involved in many abnormalities, including 
cytotoxicity, cardiac stunning, arrhythmia, apoptosis, DNA break, and reduction of 
contractility (Takano et al., 2003). ROS impairs Na+-K+-ATPase activity, resulting in 
sodium overload, which further activate the Na+-Ca2+ exchanger and lead to calcium 
overload in the sarcoplasmic reticulum (SR) ultimately. These changes collectively 
cause a loss of membrane integrity and terminally demolish the cell structure.  
Although immediate restoration of blood flow and oxygen to ischemic tissue is 
ultimately beneficial, ischemic damage may be exaggerated upon reperfusion. This 
reperfusion injury is manifested by myocardial stunning, microvascular dysfunction and 
expedition of cell death in certain critically injured myocytes. In cellular level, 
reperfusion damage could be, in part, explained by calcium overload, oxygen free 
radicals and inflammatory processes (Maxwell and Lip, 1997; Park and Lucchesi, 
1999). 
In the ischemic myocardium, contracture develops through a rigor-type 
mechanism, leading to cytoskeletal defects. These defects result in a fragile and more 
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susceptible myocardium to mechanical damage during reperfusion (Schluter et al., 
1996).  During reoxygenation, ATP synthesis assists in cardiomyocyte recovery, but 
this process also re-activates the contractile machinery which leads to uncontrolled 
Ca2+-dependent contraction (Schafer et al., 2001; Siegmund et al., 1997).  This 
increased intracellular calcium at reperfusion may also lead to calcium overload, which 
in turn may cause delayed after-depolarization and ventricular automaticity (Opie and 
Coetzee, 1988). The overloaded calcium induces maximum contraction of the 
myofibrils upon reperfusion, resulting in a disruptive type of necrosis, termed 
contraction band necrosis (Verma et al., 2002). An increase in mitochondrial [Ca2+] may 
also trigger the opening of mitochondrial permeability transition pore and lead to the 
release of cytochrome C and other pro-apoptotic factors that initiate the apoptotic 
cascade (Halestrap et al., 2004).  
  During reperfusion, oxygen is re-supplied to the myocardium, and undergoes a 
reduction process, resulting in superoxide anion formation (Di Paola and Cuzzocrea, 
2007). Forming superoxide anion is the first step in the generation of other oxygen-
derived reactive products, including hydrogen peroxide and hydroxyl radical (Park and 
Lucchesi, 1999). Neutrophils accumulate in the myocardium and become activated 
which in turn enhance oxygen free radical production (Chen et al., 1995). In the 
perfused myocardium, reoxygenated endothelial cells express adhesion proteins, release 
cytokines, and reduce production of NO which promotes adherence, activation, and 
accumulation of neutrophils in the ischemic-reperfused tissue (Ferrari et al., 1991; 
Jordan et al., 1999).  These activated neutrophils will also release reactive oxygen 
species and proteolytic enzymes that can damage myocytes and vascular cells. In 
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addition, the newly returned blood also carries white blood cells including  the 
neutrophils,  releasing pro-inflammatory lipid metabolites which have been shown to 
enhance expression and production of a pro-inflammatory cytokine cascade involving 
interleukin 1 (IL-1) and tumor necrosis factor-α (TNFα) (Clark and Lutsep, 2001); these 
cytokines then lead to the generation of other pro-inflammatory molecules (such as IL-
6, IL-8), activation and  infiltration of leukocytes, and  production of anti-inflammatory 
factors (including IL-4 and IL-10, which might produce a negative feedback on the 
cascade) (Jordan et al., 1999). 
 
1.4. Clinical Treatment 
1.4.1. First line 
Myocardial infarction is a medical emergency which demands immediate attention and 
activation of the emergency medical services. Oxygen, aspirin (antiplatelet drug), 
glyceryl trinitrate (prodrug of NO) and morphine (analgesia), hence the popular MONA 
(morphine, oxygen, nitro, aspirin), are the first line drugs recommended to be 
administered as soon as the symptoms occur (Antman et al., 2004). Once diagnosed as 
myocardial infarction, the patient is also given other pharmacologic agents, including 
beta blockers, anticoagulation (typically with heparin), and possibly additional 
antiplatelet agents such as clopidogrel (Antman et al., 2004). Nevertheless, these agents 
are typically not given until the patient is evaluated by an emergency room physician or 
under the direction of a cardiologist.  
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1.4.2. Reperfusion therapy 
The ultimate goal of the management in the acute myocardial infarction is to maintain 
the viability of as much myocardium as possible and prevent further infarction. Timely 
reperfusion of coronary flow facilitates cardiomyocyte salvage and improves their 
survival. Modalities for reperfusion include thrombolysis, percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG). 
Thrombolytic therapy achieves reperfusion by lysing the thrombi in the infarct 
artery. The effectiveness of thrombolytic therapy is determined by the timing of the 
therapeutic intervention. The best results are always observed when the thrombolytic 
agent is used within two hours of the onset of symptoms (Boersma, 2006). After 12 
hours, associated risks like intracranial or systemic bleeding outweigh any benefit 
(LATE, 1993). An ideal thrombolytic drug would lead to rapid reperfusion, possess a 
high sustained patency rate, be specific for recent thrombi, be easily and rapidly 
administered, and create a low risk for intra-cerebral and systemic bleeding (White and 
Van de Werf, 1998). Currently available thrombolytic agents are streptokinase, 
urokinase, and alteplase (recombinant tissue plasminogen activator).  
Percutaneous coronary intervention (PCI), commonly known as coronary 
angioplasty or simply angioplasty, is another effective procedure to treat the blocked 
coronary arteries by inflating a balloon within the artery to crush the thrombus. The 
procedure involves performing a coronary angiogram to determine the location of the 
blocked vessel, followed by balloon angioplasty to compress the plaque, and 
implantation of stents to prop the vessel open. The benefit of an immediate well-
performed PCI over thrombolytic therapy has been well established (Grines et al., 1993; 
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Keeley et al., 2003). However, logistic and economic obstacles seem to hinder a more 
widespread application of PCI (Boersma, 2006).  
Coronary artery bypass graft surgery is another important approach to salvage the 
blocked myocardium by reintroduction of blood supply. During the surgery, an artery or 
vein from elsewhere in the patient’s body is grafted to the coronary artery to bypass 
narrowings or occlusions. Several arteries and veins can be used; however the left 
internal thoracic artery, usually grafted to the left anterior descending coronary artery 
(LAD), have been demonstrated to last longer than great saphenous vein grafts (Raja et 
al., 2004).  Emergency CABG is less common than PCI for the treatment of an acute 
myocardial infarction. However, in patients with multiple coronary arteries occlusion, 
bypass surgery is a superior option when compared to PCI in terms of long-term 
survival rates (Hannan et al., 2005).  
It is now known that irreversible injury occurs within 2–4 hours of the infarction, 
hence there is a limited time window for reperfusion to produce beneficial results. If 
attempts to restore the blood flow are initiated a few hours after a critical period, the 
result is deterioration instead of amelioration (Faxon, 2005). Moreover, reperfusion is 
unable to reverse the tissue damage. The lost cardiomyocytes will be replaced by a 
collagen scar that is not contractible and permanently impairs the contractile function of 
the heart. Accordingly, intense interest has been directed to investigate the application 
of stem cell for the repair of heart damage. However, the therapeutic application of this 
pioneering work on acute MI and post infarction treatment requires more research to 
prove its effectiveness and safety.   
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1.5. Experimental Therapy 
1.5.1. Ischemic Preconditioning (IP) 
Experimental and clinical studies have shown that a number of interventions, including 
brief periods of ischemia-reperfusion or hypoxia-reoxygenation and certain endogenous 
mediators or pharmacological agents are able to protect the heart against myocardial 
dysfunction, arrhythmias and infarction, three hallmarks of cardioprotection (Goto et 
al., 1995; Liem et al., 2002; Ryter et al., 2007). 
In 1986 Murry and his colleagues published a landmark article in which they 
demonstrated that four repetitive 5-min episode of regional ischemia induced an 
extremely powerful protection against a subsequent lethal ischemia in anesthetized dogs. 
Infarct size was limited to 25% of that seen in the control group after 40 min of 
sustained ischemia (Murry et al., 1986). The investigators termed this phenomenon as 
‘ischemic preconditioning’ (IP). Subsequently, numerous studies documented that IP is 
similarly effect in various other models (e.g., liver, kidney, brain, and endothelial cells), 
showing that short period(s) of ischemia or anoxia could allow tissues to survive 
subsequent ischemia that would have otherwise been lethal (Sanada and Kitakaze, 
2004). Understanding this natural protection has since become one of the major targets 
in search for preventions against ischemic damages. 
While initial studies demonstrated that IP could protect the heart against sustained 
ischemia that occurred soon after preconditioning, Kuzuya et al. and Marber et al. 
independently reported in 1993 that the cardioprotective effect of IP was still detectable 
24 hours after preconditioning (Kuzuya et al., 1993; Marber et al., 1993). Kuzuya et al. 
also found that the cardioprotective effect of IP was lost between 3 and 12 hours after a 
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brief period of ischemia, indicating that there were two separate periods of 
cardioprotection afforded by IP. (Kuzuya et al., 1993) They named them the ‘‘first 
window’’ and ‘‘second window’’ respectively. The first window of the protection, often 
referred to as the classical or early phase, develops as early as few minutes after the 
preconditioning stimulus and lasts only 1–2 hours (Murry et al., 1986). The second 
window, also known as the late or delayed phase, develops 12–24 hours after the 
preconditioning stimulus, but lasts for 3–4 days (Kuzuya et al., 1993; Marber et al., 
1993). The signaling mechanisms of these two phases are different. The first phase of 
protection is initiated by posttranslational modifications of proteins that are already 
present, whereas the second phase is mediated by synthesis of de novo proteins (Bolli, 
2000).  The early phase depends on actions that occur very rapidly, such as activation of 
ion channels or phosphorylation of enzymes, whereas the late phase involves longer 
time processes such as modulation of the genes regulating channel proteins, receptor, 
enzymes, molecular chaperon proteins, or immune factors (Sanada and Kitakaze, 2004). 
However, these two types of cardioprotection seem to share the similar triggers, 
mediators, and effectors despite the differences in the timing of participation in each 
cascade. 
1.5.2. Ischemic Postconditioning 
 Despite the promising effect of IP, it has a major limitation which is that brief 
ischemia maneuver or its mimetic which can trigger pharmacological preconditioning 
has to be applied before the index ischemia insult. This has lead to the introduction of 
the concept: ischemic postconditioning (IPostC) by Na’s (Na et al., 1996) and Vinten-
Johansen’s groups (Zhao et al., 2003). IPostC is defined as the phenomenon where rapid 
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intermittent interruptions of blood flow in the early phase of reperfusion resulted in a 
reduced myocardial injury (Zhao and Vinten-Johansen, 2006). This maneuver has 
produced promising protection against ischemia-reperfusion injury in mice (Kin et al., 
2005), rats (Kin et al., 2004), rabbits (Yang et al., 2004b), dogs (Zhao et al., 2003) and 
in human patients (Staat et al., 2005).  
The main purpose of introducing shuttering during initial reperfusion phase after 
ischemia is to disrupt a process known as lethal reperfusion injury. Lethal reperfusion 
injury occurs as a result of a sudden reflow of blood into the heart which leads to an 
abrupt change in the vascular environment. This results in detrimental events which 
subsequently lead to endothelial and vascular dysfunction, metabolic dysfunction, 
contractile dysfunction, dysrhythmias and eventually myocytes necrosis and apoptosis 
(Zhao and Vinten-Johansen, 2006). The mechanisms giving rise to the protective effect 
of IPostC constitutes two arms: passive and active (Tsang et al., 2005). The passive arm 
of IPostC refers to the mechanical events and cellular events directly resulted from the 
IPostC maneuver (Vinten-Johansen et al., 2005). The mechanical events interrupts the 
sudden onset of full flow reperfusion responsible for lethal reperfusion injury such as 
the negative modulation of coronary perfusion pressure whereas the cellular events 
involves the increased nitric oxide (NO) release due to better endothelial cell survival 
and preservation of their functions (Vinten-Johansen et al., 2005). In addition to the 
passive arm, IPostC treatment activates several pro-survival kinases such as Akt (Tsang 
et al., 2004; Zhu et al., 2006), Protein Kinase C (PKC) (Philipp et al., 2006; Zatta et al., 
2006) extracellular signal regulated kinase 1/2 (ERK1/2) (Darling et al., 2005) and 
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inhibits Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase 
(MAPK) (Sun et al., 2006). These molecular events constitute the active arm of IPostC. 
1.6. Hydrogen sulfide (H2S) 
Hydrogen sulfide (H2S) has been known for hundreds years as a poisoning and toxic 
pollutant, and its best known effect is through the binding to cytochrome c oxidase 
which is responsible for its toxicity (Roth et al., 1995). However, the initial negative 
perception of H2S has evolved with the recent discovery that it is produced by a number 
of enzymes in mammalian systems and modulates several physiological processes, and 
H2S is now regarded as the third gasotransmitter alongside with nitric oxide (NO) and 
carbon monoxide (CO). In the following content, recent reports on H2S will be 
reviewed with an emphasis on its biological functions and its roles in different diseases. 
 
1.6.1.  Physical and chemical properties of H2S 
H2S is a colorless, flammable gas with a smell of rotten eggs. It is soluble in water (1 g 
in 242 ml at 20˚C) (Lim et al., 2008). H2S is also soluble in organic solvents such as 
alcohol and ether, in addition to its good solubility in alkali carbonates and bicarbonates 
(Li et al., 2009). Its good solubility in lipophilic solvents (five fold greater than in 
water) allows H2S freely penetrates cell membrane of all types. The detectable level of 
this gas by the human nose is at a concentration 400-fold lower (Wang, 2002) than the 
toxic level but prolonged exposure desensitize olfactory nerves and therefore renders 
the gas seemingly odorless to that individual (Li et al., 2009). Oxidation of H2S yields 
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elemental sulfur, sulfur oxide (SO2), and sulfates such as sulfuric acid (Wang, 2002). 
H2S is weak acid which dissociates in water or plasma as follows: 
H2S ↔ HS– + H+ ↔ 2H+ + S2- 
By using a standard Henderson-Hasselbach calculation, at physiological pH of 7.4, pKa 
of H2S is 6.755 and 7.04, which render 18.5% and 30% of the total sulfide exists as the 
undissociated form in the buffer at 37˚C and 20˚C, respectively (Dombkowski et al., 
2004). 
 
1.6.2. Biosynthesis and catabolism of H2S 
1.6.2.1. Synthesis of H2S 
The biological production and utilization of H2S have been well known for certain 
bacteria and archae (Pace, 1997). However, it is found that H2S is formed in 
mammalian tissues by both endogenous enzymes and non-enzymatic pathways (i.e. via 
reduction of thiols and thiol-containing molecules) (Li et al., 2009). Most emphasis has 
been placed on the enzymatic formation of H2S from L-cysteine by at least three 
pathways.  
In the first pathway, two L-cysteine molecules undergo dimerization to form L-
cystine, which is then transformed into thiocysteine, pyruvate and NH3 by 
cystathionine-γ-lyase (CSE, EC 4.4.1.1). CSE can further catalyze the reaction of 
thiocysteine with other thiols to form H2S (Stipanuk and King, 1982; Yamanishi and 
Tuboi, 1981). In the second pathway, L-cysteine is hydrolyzed by cystathionine β-
synthase (CBS, EC 4.2.1.22) to produce equimolar of H2S and L-serine.(Li et al., 2009; 
Szabo, 2007) In the third pathway, cysteine aminotransferase (CAT, EC 2.6.1.3) 
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catalyzes the reaction of L-cysteine with a ketoacid to form 3-mercaptopyruvate may 
then be desulphurated by 3-mercaptopyruvate sulphurtransferase (3MST, EC 2.8.1.2) to 
form H2S with a higher efficiency than CBS (Shibuya et al., 2009b). Of note, both CSE 
and CBS require pyridoxal 5’-phosphate (PLP) as cofactor to produce H2S, whereas 
3MST is zinc dependent (Li et al., 2009). 
 
1.6.2.2. Distribution of H2S-genarating enzymes 
The expression of CBS, CSE and 3MST has been detected in a board variety of cell 
types, including those from liver, kidney, thoracic aorta, ileum, portal vein, uterus, 
brain, pancreatic islets and the placenta (Nagahara et al., 1998; Shibuya et al., 2009a; 
Figure 1-3  H2S can be synthesized by at least 3 metabolic pathways (Hughes et al., 2009) 
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Shibuya et al., 2009b; Diwakar and Ravindranath, 2007; Hosoki et al., 1997; Kaneko et 
al., 2006; Kimura, 2010; Patel et al., 2009; Vitvitsky et al., 2006; Wang, 2002). In some 
tissues, both all three enzymes contribute to the local generation of H2S, whereas in 
others, one enzyme predominates. CSE is primarily expressed in the heart, vascular and 
non-vascular muscles (Li et al., 2009; Lowicka and Beltowski, 2007)  whereas CBS was 
thought to be the predominant H2S-producing enzymes in brain and nervous system but 
the idea is recently challenged by the study showing that the H2S level in the brain 
homogenates of CBS knockout mice showed no different from that of wild-type mice, 
suggesting that 3MST, which also expressed in brain, may be the main enzyme to 
generate H2S in the system (Shibuya et al., 2009b).  
1.6.2.3. Plasma and tissue H2S level  
The rate of H2S production in tissue homogenates has been reported to be about 1 – 10 
pmoles per second per mg protein, resulting in low micromolar extracellular 
concentrations (Doeller et al., 2005). Previous studies showed that both rat and human 
plasma contain approximately 50 μM of H2S (Zhao et al., 2001), and an even higher 
level of H2S (50~160 µM) was detected in the brain (Abe and Kimura, 1996). However, 
such remarkably high concentrations of H2S have recently been questioned by some 
reviews (Lim et al., 2008; Szabo, 2007) and challenged by Whitfield et al, who found 
that the free H2S gas was essentially undetectable (<100nM total sulfide) in all animals 
(Whitfield et al., 2008). In addition, they also found that H2S is rapidly consumed when 
exogenous H2S donor was added to blood (Whitfield et al., 2008), suggesting that H2S 
is not transmitted via the circulation despite its significant local physiological and 
pathological roles in different systems. Indeed, over the past decade, most researchers 
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measured H2S using a simple spectrophotometric assay which involves observation of 
color changes in acidifying zinc acetate-treated biological samples in the presence of a 
dye. Such a harsh condition may liberate sulfide from its bound forms, thereby 
producing concentrations that are likely to represent a mixture of free and bound 
sulfide. In addition, H2S is either rapidly scavenged by hemoglobin or react with 
number of reactive oxygen species abundant in tissues, renders accurate measurements 
of such a reactive gas in biological tissues or circulation difficult.  
1.6.2.4. Catabolism of H2S 
Comparatively to biosynthesis of H2S, its catabolism is poorly recognized and most data 
were obtained by using exogenous H2S (Lowicka and Beltowski, 2007) in which its 
physiological relevance is questionable. H2S is rapidly oxidized, mainly in 
mitochondria, to thiosulfate, which is then converted to sulfite and sulfate. H2S is 
excreted mainly by the kidney as free or conjugated sulfate (Beauchamp et al., 1984), 
however, it is notable that majority of sulfate in urine is believed to drive from the 
direct oxidation of cysteine by cysteine dioxygenase activity, as such, sulfate cannot be 
used as marker for the presence of H2S. Methylation by thiol S-methyltransferase to 
methanethiol and dimethylsulfide (Beauchamp et al., 1984), and binding to 
methemoglobin to form sulfhemoglobin (Wang, 2002) may be the other two H2S 
catabolism pathways in the cells. 
1.6.3. Biological role of H2S 
1.6.3.1. H2S and the central nervous system (CNS) 
The presence of considerable amounts of H2S and its synthase CBS in the brains of 
several species including humans suggested a role for this gas in CNS function (Abe 
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and Kimura, 1996). Increasing evidence shows that H2S may have a role either as a 
neuromodulator or a neurotransmitter. H2S has been shown to facilitate induction of 
hippocampal long-term potentiation by increasing the sensitivity of NMDA receptors 
(Kimura, 2000). Interaction of H2S and NMDA receptors possibly involves a cAMP-
dependent protein kinase pathway, since in the same study NaHS increases cAMP 
levels in neuronal and glial cell lines and primary neuron cultures. In addition, H2S was 
also shown to elevate the intracellular calcium in microglial cells (Lee et al., 2006), 
astrocytes (Nagai et al., 2004) and both primary culture neuron (Garcia-Bereguiain et 
al., 2008) and neuronal cell line (Yong et al., 2010), further implying the 
neuromodulatory role of H2S.  
On the other hand, H2S was reported to induce protection against glutamate-
mediated toxicity in cortical neurons (Kimura et al., 2006) and mouse hippocampal cell 
line (Kimura and Kimura, 2004), perhaps by multiple mechanisms including activation 
of KATP and Cl− channels and elevation of intracellular glutathione (Kimura et al., 
2006). Lu et al also showed that H2S may enhance glutamate uptake activity and thus 
protect primary cultured rat cortical astrocytes from H2O2-induced cellular injury via 
increase of ATP production and inhibition of ERK1/2  (Lu et al., 2008). Recently, 
NaHS was shown to be effective in treating and preventing neurotoxin-induced 
Parkinson’s disease in rat via anti-oxidative stress and metabolic inhibition, highlighting 
the therapeutic potential of H2S in neurodegenerative diseases (Hu et al., 2009). 
Abnormal production of H2S has been found to be associated with central nervous 
system diseases, such as stroke (Qu et al., 2006), Down syndrome (Kamoun et al., 
2003), and perhaps also Alzheimer's disease (Beyer et al., 2004). In the rat model of 
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stroke (Qu et al., 2006), middle cerebral artery occlusion caused an increase in H2S 
level in the lesioned cortex as well as an increase in the H2S synthesizing activity. In 
keeping with this, administration of a sulfide donor significantly increased the infarct 
volume. In subjects with Down syndrome, urinary thiosulfate (a metabolite of H2S) and 
erythrocyte sulfhemoglobin levels were both significantly increased compared with 
diet-matched controls (Kamoun et al., 2003). Further studies are warranted to determine 
whether the abnormality in H2S level is a cause or simply a consequence of these 
diseases.  
There is also growing interest in understanding the role of H2S in pain appreciation. 
Administration of either NaHS (Distrutti et al., 2006a) or an H2S-releasing derivative of 
mesalamine (Distrutti et al., 2006b) inhibited visceral nociception in the rat. Treatment 
with another H2S donor, Lawesson’s reagent, produces anti-nociceptive effect  in joint 
inflammation (Ekundi-Valentim et al., 2010). Contradictorily, it was reported that 
intraplantar injection of H2S in the hindpaw of the rat evokes pronociceptive activity 
(Kawabata et al., 2007), and intrathecal administration of NaHS causes hyperalgesia 
(Maeda et al., 2009) by an effect on T-type calcium channels, suggesting that H2S may 
be a novel mediator for pain. More experiments are warranted to determine the factors 
behind the discrepancies in the studies, which may be closely related to the ambiguous 
role of H2S in inflammation.  
1.6.3.2. H2S and Inflammation 
Extensive studies have recently been conducted to define the role of H2S in various 
inflammatory diseases. H2S was shown to induce an upregulation of anti-inflammatory 
and cytoprotective genes including haem oxygenase-1 in pulmonary smooth muscle 
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cells in vivo (Qingyou et al., 2004) and in macrophages in vitro (Oh et al., 2006). H2S 
also reduces LPS-stimulated TNF-α and NO formation in cultured microglial cells (Hu 
et al., 2007b).  In animal models of inflammation, administration of H2S donor has been 
effective in reducing carrageenan-induced paw edema and air pouch-induced leukocyte 
infiltration (Zanardo et al., 2006), the commonly-used systems to test the anti-
inflammatory effects of experimental compounds. The protective effect of H2S was 
attenuated by pretreatment with glibenclamide, suggesting the involvement of KATP 
channels. Several other studies demonstrated that chemically linking an H2S-donor 
species to known anti-inflammatory drugs can improve the therapeutic profile of the 
compound. Using a rat model of endotoxin-induced inflammation, Li and colleagues 
reported that a sulfide-releasing compound, S-diclofenac, enhanced the anti-
inflammatory effect of the parent molecule and exhibited less gastric toxicity (Li et al., 
2007). Similarly, in the study by Distrutti et al., the H2S-releasing derivative of 
mesalamine demonstrated superior anti-inflammatory efficacy compared with the base 
mesalamine molecule in the model of postinflammation hypersensitivity (Distrutti et al., 
2006b).  
However, it is intriguing that an enhanced H2S-synthesizing activity or plasma H2S 
level was observed in a large number of studies using different inflammation models. 
These include carrageenan-induced paw oedema in rats (Bhatia et al., 2005a), a mouse 
model of pancreatitis (Bhatia et al., 2005b), rodent model with endotoxic shock (Collin 
et al., 2005; Li et al., 2005), and a polymicrobial sepsis model in mice with cecal 
ligation and puncture (Marcotte and Walsh, 1975; Zhang et al., 2006). A 
pharmacological inhibitor of H2S biosynthesis, DL-propargylglycine (PAG) (Marcotte 
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and Walsh, 1975), was used in some of these studies and shown to be able to attenuate 
the inflammatory responses. In a rat model of endotoxemia, PAG prevented the 
increases in the serum levels of liver and pancreas injury markers and reduced the tissue 
content of myeloperoxidase (Collin et al., 2005). In a model of cecal ligation and 
puncture, PAG treatment reduced tissue neutrophil infiltration and improved liver and 
lung histology (Marcotte and Walsh, 1975; Zhang et al., 2006). In a carrageenan-
induced inflammation model in the rat, PAG treatment dose-dependently reduced paw 
edema and neutrophils infiltration (Bhatia et al., 2005a). 
Interestingly, both inhibitors and donors of H2S were shown to exert beneficial 
effects in the same experimental model of disease, for instance, in the carrageenan paw 
edema model (Bhatia et al., 2005a; Sidhapuriwala et al., 2007; Zanardo et al., 2006).  
While two studies demonstrate anti-inflammatory effects of H2S (Zanardo et al., 2006), 
another one argues for a pro-inflammatory role of H2S in the same model (Bhatia et al., 
2005a). It is now generally accepted that these conflicting results are due to the opposite 
effect exerted by H2S at low and high local concentrations, as well as the different speed 
of H2S release from NaHS and H2S-releasing moieties. (Li et al., 2007; Wallace, 2007) 
A similar paradox has been previously noted with inhibitors versus donors of NO — 
both of them being effective in the carrageenan paw edema models (Fernandes et al., 
2002; Handy and Moore, 1998). Clearly, there is an exquisite balance and complex 
regulation and interaction of pathophysiological responses by endogenous and 
exogenous gasotransmitters (Szabo, 2007). 
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1.6.3.3. H2S and cardiovascular system 
Earlier, it was perceived that H2S interfered with cardiovascular function as a result of 
the secondary anoxia rather than a direct action of the gas on cardiac myocytes or 
vascular smooth muscle cells (SMCs) (Reiffenstein et al., 1992). However, this view 
has been overturned by the finding of a detectable amount of H2S and its synthase CSE 
in the cardiovascular system.  
As early as in 1997, expression of CSE and endogenous production of H2S have 
been detected in rat portal vein and thoracic aorta (Hosoki et al., 1997) followed by the 
study which revealed that CSE is the only H2S-generating enzyme in rat mesenteric 
artery and other vascular tissues, with expression levels of CSE mRNA ranked in an 
order of pulmonary artery > aorta > tail artery > mesenteric artery (Zhao et al., 2001). 
On the other hand, Chen et al. found no activity or expression of CBS in human atrium 
and ventricle tissues (Chen et al., 1999). The activity and/or expression of CBS were 
also lacking in human internal mammary arteries, saphenous veins, coronary arteries, or 
aortic arteries (Bao et al., 1998; Chen et al., 1999). Thus, CSE appears to be responsible 
for the generation of H2S in cardiovascular tissues specifically. 
The effect of H2S on vascular systems has recently been investigated in several in-
depth studies. H2S at physiologically relevant concentrations induces relaxation in 
portal vein (Hosoki et al., 1997), aorta (Zhao et al., 2001), and mesenteric artery beds of 
rats (Cheng et al., 2004). A previous study by Zhao et al. revealed that an intravenous 
bolus injection of H2S at 2.8 and 14 µmol/kg body weight provoked a transient decrease 
in mean arterial blood pressure of anaesthetized rats (Zhao et al., 2001). At the tissue 
level, H2S induced a concentration-dependent relaxation of the phenylephrine (PE)-
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precontracted rat aortic tissues (IC50, 125 µM). They also found that when isolated rat 
aortic tissues were precontracted with 20 or 100 mM KCl, the maximum vascular 
relaxation induced by H2S was 90% and 19%, respectively. This difference in relaxation 
potency of H2S may represent the portion of relaxation possibly mediated by potassium 
conductance. Furthermore, the effect of H2S on aortic tone was only antagonized by the 
KATP channel blocker, glibenclamide, but not blockers of other types of potassium 
channels, indicating that the vasorelaxant effect of H2S was KATP-dependent. 
Meanwhile, they demonstrated that H2S directly increased KATP channel currents and 
hyperpolarized membrane in isolated SMCs.  
In spite of the detection of CSE in myocardial tissues, the effect of H2S on heart was 
relatively unclear. Previous studies showed that H2S was involved in the delayed 
cardioprotection induced by ischemic preconditioning, possibly via activating 
sarcolemmal KATP channels, provoking NO release (Pan et al., 2006), enhancing 
expression of different PKC isoforms (Pan et al., 2007) and COX-2 (Hu et al., 2008a). 
However, the effect of H2S in the immediate protection induced by ischemic 
preconditioning and postconditioning remains unclear.  
Geng et al. observed a negative inotropic effect of H2S in both in vitro and in vivo 
experiments, and the effect could partly be blocked by glibenclamide (Geng et al., 
2004b). As discussed in the report, the cardiac contraction could also be affected by its 
peripheral vascular effect, because H2S dilates blood vessels, which leads to reduction 
of central venous pressure, resulting in a decrease of the venous return and reduction of 
cardiac pre- and post-loads. Although this study is suggestive of a role for H2S in 
regulating cardiac function, more experiments are required to determine the role of H2S 
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in intracellular calcium and cellular contraction, in order to examine the detailed 
mechanisms.  
Accordingly, the aims of the current study are to investigate the potential role of 
hydrogen sulfide in regulating the heart functions via interaction with beta-adrenergic 
system and nitric oxide, another very important gaseous transmitter, under the 
physiological and pathological conditions. By using different methods and disease 
models, the involvement of hydrogen sulfide in cardioprotection conferred by ischemic 
pre- and post-conditioning were also examined.  
As used in numerous publications, NaHS, a donor of H2S, was employed in the 
experiments in the following chapters as its use allows for a better determination of the 
concentration of H2S in solution than bubbling H2S gas. NaHS dissociates to Na+ and 
HS- in solution. Thereafter HS- associates with H+ and produces H2S. Approximately 
one-third of the H2S in aqueous solution exists in the undissociated form (H2S) at 20 ºC 
(Abe and Kimura, 1996). At 37 ºC, the undissociated form of H2S is around 18.5% 
(Dombkowski et al., 2004) i.e. approximately 18.5 μM when 100 μM NaHS was 
applied, which is well within the range of physiological concentrations in rat plasma 
(Zhao et al., 2001). It is notable that 100 μM NaHS does not alter the pH of the buffers 
(Dombkowski et al., 2005). For this reason, NaHS has been widely used for studies on 





Chapter 2   Negative regulation of β-adrenergic function by 
hydrogen sulfide in the rat heart 
2.1. Introduction 
Hydrogen sulfide (H2S) represents the most recently identified endogenous gaseous 
messenger (Wang, 2002). The detection of plentiful H2S synthase CSE in the heart 
(Geng et al., 2004b) suggests that endogenous H2S production is important for a well-
functioned heart. However, it is not clear what the role of H2S is in pathological 
conditions. Thus I investigated whether there is a difference in endogenous H2S 
production between healthy cardiomyocytes and myocytes undergoing ischemia 
challenge.  
The β-adrenergic signaling pathway is the primary mechanism that is able to 
transiently increase cardiac output. β-adrenergic receptors are transducers linking 
hormone-mediated chemical signals to the mechanical event of augmented myocardial 
contraction (Dorian, 2005). In cellular level, the classic route of contractile function 
stimulation is the result of the activation of adenylyl cyclase (AC) catalytic activity by 
the β-adrenoceptor-coupled stimulatory G protein, which leads to increased intracellular 
cAMP level. This in turn stimulates protein kinase A (PKA), which then mediates 
phosphorylation of L-type Ca2+ channels leading to Ca2+ influx to the intracellular 
compartment. Ca2+ entry triggers Ca2+ release from sarcoplasmic reticulum and the 
elevated free intracellular Ca2+ ([Ca2+]i) bind to the myofilament protein troponin C, 
which then switch on the contractile machinery (Bers, 2002). 
Of note, it was reported that H2S production is markedly decreased during over-
stimulation of β-adrenergic system (Geng et al., 2004a). In addition, H2S was shown to 
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decrease heart contractile function including heart contractility, left-ventricular pressure 
development and left-ventricular-end systolic pressure (Geng et al., 2004b). Bearing in 
mind that the contractile state of the heart is under direct control of the adrenergic 
nervous system, I hypothesized that H2S may modulate the β-adrenergic system and this 
modulation of the β-adrenergic receptor (β-AR) may be of pathological importance 
during ischemia, which causes cardiac injury and arrhythmia due to calcium overload. 
 
2.2. Materials and methods 
All experimental protocols mentioned in this and the rest of the chapters were approved 
by the Institutional Animal Care and Use Committee of the National University of 
Singapore 
2.2.1. Isolation of adult rat cardiomyocytes 
Sprague-Dawely rats (220-300 g, male) were anesthetized with intraperitoneal (i.p.) 
injection of a combination of ketamine (75mg/kg) and xylazine (10mg/kg). Heparin 
(1000 IU) was administered i.p. to prevent coagulation during removal of the heart. The 
heart was quickly excised, mounted on a Langendorff apparatus, and perfused in a 
retrograde fashion via the aorta with calcium-free Tyrode's solution (in mmol/L): 137 
NaCl, 5.4 KCl, 1 MgCl2, 10 HEPES, 10 Glucose, pH 7.4 at 37 °C. After 5 min the 
perfusion solution was changed to the Tyrode's solution containing 1 mg/ml collagenase 
type I and 0.28 mg/ml protease (type XIV) and perfused for a further 25-30 min. The 
perfusion solution was then changed to Ca2+-Tyrodes solution containing 2 × 10−4 
mol/L CaCl2 without enzymes for an additional 5 min. The ventricular tissue was then 
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cut into small pieces in a Petri dish containing pre-warmed Ca2+ Tyrode's solution and 
shaken gently to ensure adequate dispersion of dissociated cardiac myocytes. A 
2.5 × 10−4 meter mesh screen was used to separate the isolated cardiac myocytes from 
cardiac tissue. The cells were then washed three times in Ca2+-Tyrode's solution and 
collected by centrifugation (500 rpm, for 1 min). Ca2+ concentration of the Tyrode's 
solution was increased gradually to 1.25 × 10−3 mol/L in 20 min. More than 70% of the 
cells were rod-shaped and impermeable to trypan-blue. The cells were allowed to 
stabilize for 30 min before any experiments. 
2.2.2. Measurement of H2S concentration 
The culture media of cardiomyocytes were collected for measurement of endogenous 
H2S production. 75 μL media from each sample was added into an Ependorff tube that 
already contained 450 μL deionised water and 250 μL zinc acetate (1% w/v). Then N, 
N-dimethyl-p-phenylenediamine sulphate (20 μM in 7.2 mol/L HCl, 133 μl) and FeCl3 
(30 μM in 1.2 mol/L HCl, 133 μL) were added in sequence for color development at 
room temperature. After 10 min, trichloroacetic acid (10% w/v, 250 μL) was added to 
precipitate any protein that might be present in the media. The tubes were then 
centrifuged (10,000 × g) for 3 min and 300 μl aliquots from the resulting supernatants 
were transferred into a 96-well plate. Absorbance was determined at 670 nm using a 96 
well microplate reader (Tecan Systems Inc., U.S.A.). 
2.2.3. Measurement of contractile and relaxation function 
Twitch amplitudes of cells were recorded and measured as described previously.(Hu et 
al., 2007a) Briefly, cell images were  also continuously monitored through a x40 
objective lens (Nikon, Singapore) and transmitted to a charge-coupled device (CCD) 
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black and white (B/W) video camera (NL-2332; National Electronic, Canada). The 
output from the CCD camera was displayed on a video monitor (National Electronic, 
Canada). Myocyte edge was measured using a video motion edge detector (VED-105; 
Crescent Electronics, Canada). Light-dark contrast of the edge of the myocytes provides 
a marker for measurement of the amplitude of motion. The amplitude of marker was 
directly proportional to the dark image of contraction and the action was in real time. 
The amplitude of myocyte motion remained unchanged for at least 10 min, indicating 
the stability of the preparation. The data collection time point was set to be 1000 sec 
after drug treatments, since maximum response reached at less than 900 sec after drug 
administration. This was also applied to calcium transient amplitude data collection 
throughout the study. The maximum velocity of cell shortening (-dL/dt) and relaxing 
(+dL/dt) is represented by average value of maximum changes of length/time of at least 
five continuous tracing in each cell, at 1000 s after each treatment. 
2.2.4. Measurement of intracellular Ca2+ ([Ca2+]i) 
Ventricular myocytes were incubated with fura-2/AM (4 × 10−6 mol/L) (25 min) in 
Tyrode's solution supplemented with 1.25 × 10−3 mol/L CaCl2. The unincorporated dye 
was removed by washing the cells twice with fresh incubation solution. Loaded cells 
were kept at room temperature (24 °C-26 °C) for 30 min to allow the fura-2/AM in the 
cytosol to de-esterify. 
Loaded ventricular myocytes were then transferred to the stage of an inverted 
microscope in a superfusion chamber at room temperature. The inverted microscope 
was coupled with a dual-wavelength excitation spectrofluorometer (Intracellular 
imaging Inc, USA). Myocytes were perfused with Krebs' bicarbonate buffer (KB buffer, 
  
39
mmol/L; 117 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.25 CaCl2, 25 NaHCO3, 11 
glucose, with 1% w/v dialyzed BSA) and gassed with 95% O2/5% CO2. The myocytes 
selected for the study were rod-shaped with clear striations. These cells exhibited 
synchronous contraction (twitch) in response to suprathreshold (4 ms, 0.2 Hz) stimuli 
delivered by a stimulator (Grass S88, Canada) via two platinum field-stimulation 
electrodes immersed in the bathing fluid. Fluorescent signals obtained at 340 nm (F340) 
and at 380 nm (F380) excitation wavelengths were stored in a computer for data 
processing and analysis. The F340/F380 ratio was used to indicate [Ca2+]i level in the 
myocytes. 
2.2.5. Assay of cAMP 
The cAMP produced in the cells from different treatment groups were sampled and 
measured according to the instruction provided in the direct cAMP enzyme 
immunoassay kit purchased from Sigma-Aldrich (St. Louis, MO, USA). The pellets 
were stored at -20ºC for protein determination. Data were compared to a standard curve 
to obtain the actual cAMP concentrations. 
2.2.6. Cell fractionation and adenylyl cyclase activity assay 
A cell fractionation technique was adopted from the literature (Mackay and Mochly-
Rosen, 2001a; Weber et al., 2005) and described in our previous publication (Pan et al., 
2007). Adenylyl cyclase activity was assayed as described previously with some 
modifications (Lin et al., 2002). The adenylyl cyclase (AC) activity assay was 
performed at 37ºC for 10 min in a 400 μL reaction mixture containing 1 mM ATP, 100 
mM NaCl, 50 mM Hepes, 0.5 mM 3-isobutyle-1-methylxanthine, 6 mM MgCl2, 1 μM 
GTP, and 20 μg of membrane protein. In forskolin group, samples were treated with 
  
40
forskolin (100 μM) for 10 min. In Forskolin+NaHS group, NaHS (100 μM) was given 5 
min before and during forskolin treatment. Reactions were stopped by addition of 0.6 
mL of trichloroacetic acid (10% w/v). The accumulation of cAMP was later assayed by 
cAMP EIA kit (Cayman Chemical, USA). 
2.2.7. Statistical analysis 
Values presented are mean ± standard error of mean. SPSS for Windows (11.5.0, LEAD 
technologies, USA) was used to perform the analysis. One-way analysis of variance 
(ANOVA) was used to determine the difference among groups. A post hoc Bonferroni 
analysis was used to determine the significant differences between the groups. The 
significance level was set at P<0.05.  
2.2.8. Drugs and Chemicals 
Type 1 collagenase, protease XIV, isoproterenol, forskolin, 8-bromoadenosine-3’,5’-
cyclic monophosphate,  NaHS, and N, N-dimethyl-p-phenylenediamine sulphate, FeCl3 
isobutyle-1-methylxanthine and caffeine were purchased from Sigma Chemical Co, 
USA. Fura-2 was purchased from Molecular Probes Inc. USA. Bay K-8644 and GTP 




2.3.1.  Effect of NaHS on isoproterenol-augmented contraction in  
electrically-stimulated ventricular myocytes. 
Figure 2-1A shows the representative tracings of the effect of ISO (0.5 μM) on myocyte 
contraction in the presence and absence of NaHS (100 μM). Stimulation of β-
adrenoceptor with ISO significantly increased the twitch amplitude (Figure 2-1B), 
maximal velocity of cell shortening (+dl/dt), and maximal velocity of cell relaxing (-
dl/dt, Figure 2-1C) of the single ventricular myocytes. Pretreatment with NaHS (100 
µM) for 5 min, which itself had no effect, significantly attenuated the effect of ISO 
(0.5μM) on these parameters (Figure 2-1B & 2-1C) (n = 7. p<0.001 for ISO vs control 
group; p<0.01 or 0.05 for NaHS+ISO vs ISO group). The concentration-dependent 
effect of ISO on myocyte twitch amplitude was shown in Figure 2-1D. ISO at 10-10 to 
10-6 M increased the electrically-induced contraction of the single ventricular myocytes 
in a concentration-dependent manner. The maximal effect of ISO (Emax) was 86.4 ± 
8.6% of control (before ISO treatment) and the EC50 value was 60.1 nM. Pretreatment 
with NaHS (100 μM) for 5 min significantly attenuated the effect of ISO at a 
concentration range from 5×10-8 to 10-6 M. (n = 6-7, p<0.05 or 0.01, Figure 2-1D). The 
Emax and EC50 of ISO (Emax) were decreased to 50.7 ± 8.9% and 5.68 nM, 
respectively, in NaHS treatment group. The concentration-dependent effect of NaHS 
was shown in Figure 2-1E, NaHS at 10-5 to 10-3 M concentration-dependently 
attenuated ISO (0.5 µM)-augmented cell contraction (n = 6-7, p<0.05 or 0.01, Figure 2-
1E). Taken together, these data suggest that H2S attenuates the myocytes twitch 




Figure 2-1  Inhibitory effect of NaHS on ISO augmented contraction in electrically-stimulated rat 
ventricular myocytes. (A) Representative tracings of myocytes twitch amplitude of control, ISO (0.5 µM), NaHS 
(100 µM) and NaHS+ISO treatment group. (B & C) Group data showing that NaHS (100 µM) attenuated the effect 
of ISO (0.5 µM) on twitch amplitude (B) and maximal velocity of cell shorterning and relaxing (C). Mean±S.E.M, 
n = 7 for each group, ##p<0.01, ###p < 0.001 vs control; *p<0.05, **p< 0.01 vs ISO group. (D) Concentration-
dependent effect of ISO on myocyte twitch amplitude in the presence and absence of NaHS. The cells were treated 
with NaHS (100 µM) for 5 min before administration of ISO at the concentration range from 10-10 to 10-6 M. 
Mean±S.E.M, *p<0.05 and **p<0.01 vs corresponding value in ISO group. (E) Concentration-dependent effect of 
NaHS (10-5 to 10-3 M) on ISO (0.5 µM)-augmented contraction in the electrically-stimulated ventricular myocytes 
pretreated with NaHS. Mean±S.E.M, n = 6-7, *p<0.05 and **p<0.01 vs ISO alone group.  
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2.3.2. Effect of NaHS on ISO-augmented [Ca2+]i transients in electrically-
stimulated ventricular myocytes  
To determine the effect of H2S on calcium handling, I observed the effect of H2S on the 
amplitude of electrically-induced (EI) [Ca2+]i transients upon ISO treatment. As shown 
in Figure 2-2A, the amplitude of electrically-induced [Ca2+]i transients was significantly 
augmented by ISO (0.5 µM), which was attenuated by pretreatment with NaHS (100 
μM) for 5 min (Figure 2-2B). Data are presented as ∆[ Ca2+]i transient amplitude by 
measuring the difference of [Ca2+]i transient amplitudes between before and after drug 
treatment. Figure 2-2C shows that NaHS significantly attenuated the effect of ISO on 
electrically-induced [Ca2+]i transients (∆[Ca2+]i transient amplitude: ISO group: 0.46 ± 
0.07; NaHS+ISO group: 0.06 ± 0.01; n = 5, p<0.05, Figure 2-2C).  
In order to assess the involvement of sarcoplasmic reticulum (SR) Ca2+-ATPase 
(SERCA) in this inhibitory regulatory effect of H2S, I assessed the decline rate of EI-[ 
Ca2+]i , an indicators of SR- Ca2+ uptake rate.(Pan et al., 2007) Figure 2-2D and 2-2E 
shows that both t50 (half-decay time) and t90 (90%-decay time) were greatly shortened 
by ISO treatment. Despite attenuating the effect of ISO on cell shortening and relaxing 
velocities, H2S failed to alter the SR- Ca2+ uptake rate accelerated by ISO.  These data 
suggest that the effect of H2S on myocyte contraction is not via affecting the Ca2+ 
uptake by SERCA. 
I also observed whether NaHS changes the calcium response kinetics to ISO. 
The maximum calcium response of myocyte to ISO reached within 900 sec after 
treatment. The EI-[ Ca2+]i transient peak/time curve  (shown by arrows in Figure 2-2A-
B) upon ISO treatment was well fitted with the Boltzmann sigmoidal function. I found 
that NaHS did not significantly change the time to reach 20% (t20), 50% (t50) and 80% 
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(t80) of maximum response, suggesting that NaHS had no effect on the response kinetic 
profile of ISO treatment (Figure 2-2F). Taken together, our data indicate that the 
inhibitory effect of H2S appears to be primarily via modulation of the β-adrenergic 





















Figure 2-2 Inhibitory effect of NaHS on ISO-augmented [Ca2+]i transients in the electrically-
stimulated ventricular myocytes. (A-B) Representative tracings showing the effect of 0.5 μM ISO on 
[Ca2+]i in the ventricular myocytes pretreated with (B) and without (A) of 100 μM NaHS. The time scale 
for time-expanded section and compressed section are indicated separately. • Electrical stimulation, each • 
is separated by 5 sec. (C - F) Group data showing the effect of NaHS (100 μM) on ISO-augmented 
calcium transient amplitudes (C), decay time of EI-[Ca2+]i transients (D, t50: half-decay time; E, t90: 
90%-decay time)  and calcium response kinetics to ISO (F, t20, t50 and t80 indicate the time to reach 20%, 
50% and 80% of maximum response respectively) and Mean±S.E.M, n = 5, #p<0.05 vs control, *p<0.05 
vs ISO group.  
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2.3.3. Effect of NaHS on forskolin-augmented [Ca2+]i transients and 
contraction in electrically-stimulated ventricular myocytes 
Stimulation of β-adrenergic system activates adenylyl cyclase. To determine whether 
H2S acts on adenylyl cyclase, forskolin (an activator of adenylyl cyclase) was used. 
Forskolin (0.5 μM) significantly increased the amplitudes of electrically-induced [Ca2+]i 
transients (Figure 2-3A) and myocyte twitch (Figure 2-3C) of the single ventricular 
myocytes. Pretreatment with NaHS (100 μM) attenuated these effects (∆[Ca2+]i  
transients amplitude: Forsk group: 0.26 ± 0.05%; NaHS+Forsk group: 0.05 ± 0.02%; n 
= 5, p<0.05; ∆twitch amplitude: Forsk group: 60.4 ±1%; NaHS+Forsk group: 39.3 ± 
5%; n = 5, p<0.01, Figure 2-3E). Figure 2-3F and 2-3G show that H2S attenuated the 
effect of forskolin on ±dl/dt but not on EI-[ Ca2+]i decay. There was no significant 
difference in t20, t50 and t80 between forskolin and forskolin+NaHS groups (Figure 2-
3H), suggesting that the response kinetics of forskolin did not differ between the groups 
with or without treatment of NaHS. These data indicate that H2S may act on adenylyl 







Figure 2-3 Inhibitory effect of NaHS on forskolin augmented [Ca2+]i transients and twitch amplitude 
in the electrically-stimulated ventricular myocytes. (A-D) Representative tracings showing the effect of 
0.5 μM forskolin on [Ca2+]i transients (A & B) and myocyte twitch amplitude (C & D) in the ventricular 
myocytes in the absence (A & C) and presence (B & D) of 100 μM NaHS. The time scale for time-expanded 
section and compressed section in [Ca2+]i transient tracings are indicated separately. • Electrical stimulation, 
each • is separated by 5 sec. (E-H) Group data showing the effect of NaHS (100 μM) on forskolin-
augmented amplitudes of electrically-induced [Ca2+]i transients and myocyte twitch (E), maximal velocities 
of cell shortening and relaxing (F), decay rate of EI-[Ca2+]i transients (G) and calcium response kinetics (H).  




2.3.4. Effect of NaHS on 8B-cAMP-augmented [Ca2+]i transients and 
contraction in electrically-stimulated ventricular myocytes    
To delineate whether the effect of H2S is via altering cAMP/PKA pathway, 8B-cAMP 
(a cellular membrane-permeable cAMP analog) was employed. As shown in Figure 2-
4A and 2-4C, 8B-cAMP at 0.5 mM also obviously increased both electrically-
stimulated [Ca2+]i transients and twitch amplitude. However, NaHS failed to attenuate 
both the parameters enhanced by 8B-cAMP (∆[Ca2+]i transients amplitude: 8B-cAMP: 
0.23 ± 0.04 NaHS+8B-cAMP group: 0.23 ± 0.06; n = 6, p = 0.87; ∆twitch amplitude: 
8B-cAMP: 49 ± 10%; NaHS+8B-cAMP group: 49 ± 6%; n = 5, p = 0.99, Figure 2-4E). 
Figure 2-4F and 2-4G show that H2S did not alter the effect of 8B-cAMP on both ±dl/dt 
and EI-[ Ca2+]i decay. The calcium response kinetics of 8B-cAMP again showed no 
difference between the groups in the presence or absence of NaHS (Figure 2-4H). These 

















Figure 2-4  NaHS failed to alter the effects of 8B-cAMP on [Ca2+]i transients and twitch amplitude 
in the electrically-stimulated ventricular myocytes. (A-D) Representative tracings showing the effect 
of 0.5 mM 8B-cAMP on electrically-induced [Ca2+]i transients (A & B) and twitch amplitude (C & D) 
in the ventricular myocytes in the absence (A & C) and presence (B & D) of 100 μM NaHS. The time 
scale for time-expanded section and compressed section in [Ca2+]i transient tracings are indicated 
separately. • Electrical stimulation, each • is separated by 5 sec. (E-H) Group data showing the effect of 
NaHS (100 μM) on 8B-cAMP-augmented amplitudes of electrically-induced [Ca2+]i transients and 
myocyte twitch (E), maximal velocities of cell shortening and relaxing (F), decay rate of EI-[Ca2+]i 




2.3.5. Effect of NaHS on Bay K-8644-augmented [Ca2+]i transients and 
contraction in electrically-stimulated ventricular myocytes  
Bay K-8644 (BayK) is a specific L-type Ca2+ channel agonist. I found that BayK (0.5 
µM) significantly increased both amplitudes of [Ca2+]i transients and myocyte twitch in 
electrically-stimulated ventricular myocytes (Figure 2-5A & 2-5C). These effects was 
not affected by H2S (∆[Ca2+]i transients amplitude: BayK group: 0.23 ± 0.05; 
NaHS+BayK group: 0.25 ± 0.09; p = 0.64, n = 5; ∆twitch amplitude: BayK group: 39 ± 
5.2%; NaHS+BayK group: 29 ± 2%; p = 0.10, n = 5; Figure 2-5E). There was also no 
significant difference in ±dl/dt and decay rate of EI-[ Ca2+]i and calcium response 
kinetics between the groups with or without NaHS treatment (Figure 2-5F-H). These 






















Figure 2-5 NaHS failed to alter the effects of BayK on [Ca2+]i transients and twitch amplitude in the 
electrically-stimulated ventricular myocytes. (A-D) Representative tracings showing the effect of 0.5 μM 
BayK on electrically-induced [Ca2+]i transients (A & B) and twitch amplitude (C & D) in the ventricular 
myocytes in the absence (A & C) and presence (B & D) of 100 μM NaHS. The time scale for time-expanded 
section and compressed section in [Ca2+]i transient tracings are indicated separately. • Electrical stimulation, 
each • is separated by 5 sec. (E-H) Group data showing the effect of NaHS (100 μM) on BayK-augmented 
amplitudes of electrically-induced [Ca2+]i transients and myocyte twitch (E), maximal velocities of cell 
shortening and relaxing (F), decay rate of EI-[Ca2+]i transients (G) and calcium response kinetics (H).  




2.3.6. Effect of NaHS on the elevated production of cAMP by ISO in rat 
ventricular myocytes 
To further determine whether a cAMP-dependent pathway was involved in the 
interaction between H2S and β-adrenergic receptor, I studied the effects of H2S on ISO-
stimulated and basal cAMP production in the rat ventricular myocytes. As shown in 
figure 2-6A, ISO (0.5 μM) significantly elevated the intracellular cAMP level, which 
was markedly attenuated by 100 μM NaHS, which alone did not significantly altered 
cAMP level. (Control group: 5.4 ± 0.4 pmol/mg protein; NaHS alone: 3.8 ± 0.5 
pmol/mg protein; ISO group: 9.6 ± 1.0 pmol/mg protein; NaHS+ISO group: 6.2 ± 0.7 
pmol/mg protein; n = 8-10, p < 0.01 for both Control vs ISO and ISO vs NaHS+ISO; 
Figure 2-6A). 
2.3.7. Effect of NaHS on adenylyl cyclase activity in isolated rat hearts 
I further examined whether the decreased cAMP production by NaHS is caused by 
inhibition of adenylyl cyclase. As shown in Figure 2-6B, forskolin (100 μM) stimulated 
adenylyl cyclase activity from 582 ± 85 pmol cAMP/mg protein/min to 1103 ± 139 
pmol cAMP/mg protein/min (n = 11, p<0.01). NaHS at 100 μM significantly attenuated 
this effect (685 ± 106 pmol cAMP/mg protein/min; n = 11, p<0.05), suggesting that the 















2.3.8.  Effect of β-adrenergic stimulation on the production of H2S in rat 
ventricular myocytes 
Since β-adrenoceptor is over-stimulated during ischemia(Schomig and Richardt, 1990), 
I further examined whether β-adrenergic over-stimulation contributes to the lowered 
endogenous H2S production in ischemia. The isolated cardiac myocytes were incubated 
with 10 μM ISO for 3 hours. As shown in Figure 2-7, ISO significantly decreased H2S 
production in rat ventricular myocytes by 55±5.5% (n = 4, p<0.01). This result suggests 








Figure 2-6 Effect of NaHS on cAMP production and AC activity in rat isolated cardiomyocytes or 
isolated hearts. (A) NaHS (100 μM) lowered intracellular cAMP stimulated by ISO in rat ventricular 
myocytes. Mean±S.E.M, n = 8-10, ##p<0.01 vs control; **p<0.01 vs ISO. (B) NaHS (100 μM) inhibited AC 





Figure 2-7 Effect of ISO on H2S production in rat ventricular myocytes. Treatment 
with ISO (10 μmol/L) for 3 hours significantly decreased H2S production in rat 






The β-adrenergic receptor (AR) is the predominant post synaptic receptor to the 
sympathetic nervous innervations in the heart. It is conveniently categorized into 2 
distinct subtypes, β1 and β2 receptors. Isoproterenol (ISO), a non-selective β-AR 
agonist, acts on both β1 and β2 receptors. It has been recognized that β1-AR is the 
predominant AR expressed by cardiomyocytes and β2-AR–dependent signals may 
represent only a relatively minor component of catecholamine responsiveness under 
normal physiological conditions (Molenaar and Parsonage, 2005). For this reason, the 
results presented in this study may indicate, to a greater extent, the effect of H2S on the 
β1-adrenergic system signaling pathway. ISO has a stronger affinity to β-AR than that 
of norepinephrine, and the results obtained from the experiments using ISO are 
generally more physiological relevant than that using selective agonist for β1 receptor. 
In the present study, I found that H2S significantly attenuated the amplitudes of both 
electrically-induced [Ca2+]i transients and myocyte twitch upon β-adrenergic 
stimulation. The effect of H2S is dependent on the action of ISO. H2S only attenuated 
myocyte contraction stimulated by ISO ranged from 5x10-9 to 10-6 M, but not at lower 
concentrations (10-10~10-9 M). Since ISO at 10-10-10-9 M does not significantly increase 
cAMP levels (Vila Petroff et al., 2001), our data suggest that H2S may negatively 
regulate β-AR when it is activated. 
Activation of β-AR stimulates Gs-protein/adenylyl cyclase, which in turn 
increases intracellular cAMP level and therefore activates PKA. Activation of PKA 
phosphorylates key components of the calcium handling and contractile machinery. I 
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then studied the action mechanism of H2S by stimulating different enzymes/channel 
proteins in the signaling cascade of β-AR system. I found that H2S significantly 
attenuated the effects of ISO and forskolin, but failed to alter the effects of 8B-cAMP 
and BayK on amplitudes and velocities of myocyte contraction/relaxation and 
amplitudes of EI-[ Ca2+]i transients. To further confirm the exact action site of H2S on 
β-adrenergic system, I examined the effect of NaHS on intracellular cAMP level and 
AC activity. It was found that NaHS markedly attenuated ISO-elevated intracellular 
cAMP and forskolin-stimulated AC activity, indicating that H2S may negatively 
regulate β-AR function through inhibition of cAMP/PKA pathway. Since the ISO-
induced activation of PKA phosphorylates and opens L-type calcium channels in the 
plasma membrane, H2S may therefore attenuate ISO augmented amplitudes of EI-[ 
Ca2+]i transients and myocyte contraction.  
Activation of PKA may also phosphorylate phospholamban (Simmerman and 
Jones, 1998) which, in turn, stimulates Ca2+ uptake through SERCA. Since I found that 
NaHS inhibited cAMP/PKA pathway, the up-regulated SERCA activity by ISO should 
also logically be inhibited by NaHS. However, I failed to see this response in this study. 
This may be related to other indirect effects of H2S. I previously reported that H2S 
preconditioning activates PKC which may, in turn, enhance SR-Ca2+ uptake (Pan et al., 
2007). This stimulatory effect via PKC may compensate/counteract the inhibitory effect 
of H2S on SERCA via suppressing cAMP/PKA pathway. This therefore causes the 




In addition to cAMP/PKA pathway, a recent study demonstrated that a novel 
pathway downstream of β-AR involving the cAMP-dependent Rap GTP exchange 
factor (Epac) and PLCε regulates Ca2+-induced Ca2+ release (CICR) in cardiac 
myocytes (Oestreich et al., 2007). It was found that, cAMP-dependent activation of 
Epac is also required for maximal β-AR stimulation of CICR in the myocardium. 
Smrcka et al indicated that 50-60% of β-AR dependent increase in CICR is attributed to 
PKA with the remaining 40-50% attributed to Epac-Rap-PLC pathway.(Smrcka et al., 
2007) These studies further highlight the effectiveness of H2S as a regulator of myocyte 
contractility since here I reported that H2S may inhibit both cAMP related pathways.  
H2S has also been shown to open the KATP channels in vascular smooth muscle 
cells (Wang, 2002) and cardiac myocytes (Bian et al., 2006; Pan et al., 2006). Opening 
of the KATP channel generates an outward current and changes the membrane potential 
and causes hyperpolarisation, which may in turn inhibit the calcium influx via L-type 
Ca2+ channel and prevent Ca2+ overload. However, the involvement of the KATP channel 
in this H2S-mediated-negative modulation of β-adrenergic stimulation may be 
insignificant due to the observations that H2S did not affect the actions of 8B-cAMP and 
BayK on the [Ca2+]i transients and contraction augmentation. This is supported by the 
findings from several groups. Firstly, ISO was shown to be able to open KATP channel in 
coronary smooth muscle cell through stimulation of cAMP/PKA pathway (Wellman et 
al., 1998). Thus, ISO may also activate KATP channel in cardiac myocytes by the same 
pathway. For this reason, H2S may not exert any significant regulative effect on β-
adrenergic stimulation through opening of the KATP channel. Secondly, it has been 
reported that myocytes KATP channels play a negligible role in modulating intact in vivo 
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cardiac contraction or arrhythmia in normal and failing heart with and without increased 
metabolic demand and regional ischemia (Saavedra et al., 2002). These data support our 
findings that H2S negatively regulated β-adrenergic function is via inhibition of cAMP 
production but not via activation of KATP channels.  
In myocardial ischemia, sympathetic activity in the heart is closely linked with 
the progression of cell injury and the incidence of ventricular arrhythmias (Schomig, 
1990). Excess norepinephrine release and accumulation in hearts may induce number of 
physiological processes including depletion of ATP and accumulation of intracellular 
Ca2+ and Na+ (Cascio et al., 2005), all of which play important roles in the genesis of 
ventricular arrhythmias (Omerovic et al., 2007). Therefore, H2S may antagonize 
negative consequences of sympathetic overactivation during ischemia by generating 
negative feedback to cAMP production. In this context, H2S replacement therapy may 
be a significant cardioprotective and anti-arrhythmic intervention for those patients with 
chronic ischemic heart disease whose plasma H2S level was found to be reduced. (Jiang 
et al., 2005)  
A clinical observational study has shown that the plasma concentration of H2S in 
patients with coronary heart disease was significantly lowered in comparison with that 
in normal control subjects, suggesting that decreased plasma H2S levels may correlate 
with the severity of coronary heart disease (Jiang et al., 2005). In the present study, I 
showed that over-stimulation of β-AR by ISO reduced the endogenous production of 
H2S. This is consistent with our previous report that ischemia decreases endogenous 
H2S production in ventricular myocytes (Bian et al., 2006). In addition, Geng et al has 
also showed that reduced myocardial and plasma H2S levels were found in the rats 
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injected with ISO.(Geng et al., 2004a) These reports strongly imply that reduced H2S 
level caused by ischemia and β-adrenoceptor over-stimulation may result in the 
impairment of the negative modulation of H2S on β-adrenoceptor system, and hence 
calcium overload. Our findings may provide a novel mechanism of ischemia-induced 
myocardial injury and arrhythmia. 
The mechanisms of ISO-induced disturbance of the CSE/H2S pathway are 
unclear. CSE is a key enzyme for H2S production in heart and its activity depends on 
pyridoxal 5’-phosphate (PLP), which is reduced in ischemic disease such as stroke 
(Kelly et al., 2004). Thus, ISO may mimic the ischemic condition and result in lowered 
PLP levels, which might inhibit the CSE activity and cause decrease in H2S generation. 
In neonatal cardiac myocytes, it has been reported that ISO may elicit transient release 
of NO (Anuar et al., 2006), which has been shown to down-regulate CSE mRNA level 
(Kanai et al., 1997). Therefore, the inhibited biosynthesis of H2S by ISO may also via 
altering NO release.  
In conclusion, the present study has demonstrated for the first time that 
exogenous application of H2S at biological-relevant concentration negatively regulates 
β-adrenergic function via inhibition of adenylyl cyclase. Sympathetic regulation of 
cardiac function is important for the normal response of the heart to stress. Perturbation 
of β-adrenergic signaling significantly contributes to progressive heart failure. Our 
study therefore not only demonstrates a significant cardioprotective intervention, but 






Chapter 3   Role of Hydrogen Sulfide in the Cardioprotection 
Induced by Ischemic Preconditioning 
3.1.  Introduction 
In the previous chapter, it was found that H2S negatively regulates beta-adrenergic 
function, which suggests that H2S may be cardioprotective against ischemia/reperfusion 
injury, when the beta adrenergic system is over-stimulated (Schomig et al., 1984). As 
such, in this chapter, I continued to study whether preconditioning with H2S can protect 
the heart against ischemic injury and the contribution of H2S in the cardioprotection 
caused by ischemic preconditioning (IP). 
Ischemic preconditioning (IP) refers to the phenomenon that previous exposure to 
brief sublethal ischemia provides protection on the heart against subsequent severe 
ischemia insults (Murry et al., 1986). It is a powerful natural cardioprotective 
mechanism. A pivotal signaling event during IP is the opening of KATP channels 
(Sanada and Kitakaze, 2004). The ability of H2S to open KATP channels in smooth 
muscle cells (Zhao et al., 2001) prompted us to investigate whether endogenous H2S 
also plays a part in the IP-induced cardioprotection. 
3.2. Materials and methods 
3.2.1.  Assessment of cell viability and morphology 
Trypan blue exclusion was used as an index of myocyte viability (Zhou et al., 1996; 
Hiebert and Ping, 1997). After cells were incubated with 0.4% (w/v) trypan blue dye for 
3 min, living cells were unstained and termed nonblue cells. Nonblue cells/total cells 
were determined in a hemocytometer chamber using a light microscope (10x 
magnification). Cell morphology was also assessed by microscopic examination. 
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Percentage of rod-shaped (length/width ratio, >3:1) cells were determined as an 
indicator of the percentage of healthy cardiomyocytes. 200-500 cells in each of 5-7 
cultures were tested for each group. Percentage of rod-shaped (length/width ratio, >3:1) 
cells were determined as an indicator of the percentage of healthy cardiomyocytes. 200-
500 cells in each of 5-7 cultures were tested for each group. 
 In in vitro myocytes study, the ischemic solution (pH 6.6 containing 2 x 10-2 
mol/L lactate and 10-2 mol/L 2-deoxy-D-glucose (2-DOG), an inhibitor of glycolysis)  
was used according the protocol shown in Figure 3-2 A, to mimic the ischemic 
condition in the heart.  
3.2.2. Statistical Analysis 
Values presented are mean ± standard error of mean. SPSS for Windows (11.5.0, LEAD 
technologies, USA) was used to perform the analysis. One-way analysis of variance 
(ANOVA) was used to determine the difference among groups. A post hoc Bonferroni 
analysis was used to determine the significant differences between the groups. The 
significance level was set at P<0.05 
3.2.3. Isolated Perfused Rat Heart Preparation 
Sprague-Dawley rats (230-270 g, male) were anesthetized with 200 mg/kg 
pentobarbitone by intraperitoneal (i.p.) injection.  Heparin (1000 IU) was administered 
i.p. to prevent coagulation during removal of the heart.  The heart was removed, 
mounted in a Langendorff apparatus and perfused retrogradely through the aorta with a 
Krebs solution containing (mM; 117 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.25 
CaCl2, 25 NaHCO3 and 11 glucose) and bubbled with 95% O2/5% CO2 (pH 7.4, 34 oC), 
at a constant flow rate of 13 ml/min as described previously (Bian et al., 2000). The 
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Electrocardiogram (ECG) was monitored continuously and recorded with two 
electrodes hooked to the apex and the aorta respectively. Each heart was allowed to 
stabilize for 15 min before the experiment commenced. Any heart that exhibited 
arrhythmias during this period was discarded. 
 The experimental design for the sodium hydrogen sulfide preconditioning (SP) 
and IP protocols is shown in Figure 1A. In the vehicle preconditioning (VP) group, 
hearts were superfused for 40 min with Krebs solution (13 ml/min) and then subjected 
to a low flow ischemia insult (perfusion rate, 0.5 ml/min, 30 min) followed by 10 min 
of reperfusion. For the preconditioning group, hearts were subjected to 3 cycles of 3 
min of perfusion with sodium hydrogen sulfide (NaHS) (100 μM, SP) or low flow 
ischemia insults (perfusion rate 0.5 ml/min, IP) separated by 5 min of superfusion with 
normal Krebs solution at normal perfusion rate (13 ml/min).  After SP or IP, hearts were 
subjected to low flow ischemia insults for 30 min followed by 10 min reperfusion as in 
the VP group. In an attempt to determine the involvement of H2S formation in the 
cardioprotection induced by IP, either DL-propargylglycine (PAG, 2 mM) or β-cyano-
L-alanine (BCA, 1 mM) (both CSE inhibitors) were given 15 min before as well as 
during IP (Figure 1A). The concentration of such drug chosen was based on a previous 
study.(Mok et al., 2004) 
3.2.4. Arrhythmia Scoring System 
In order to quantify arrhythmias, the scoring system of Curtis and Walker (Curtis and 
Walker, 1988) was used with modifications. Since the arrhythmias induced by 
ischemia/reperfusion in the present study were mainly ventricular premature beats and 
ventricular tachycardia (VT), scoring emphasis was placed on ventricular arrhythmias. 
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The scoring system adopted was therefore as follows: 0: no arrhythmia; 1: 1-30 
premature ventricular contraction (PVC); 2: >30 PVC; 3: <3 episode of ventricular 
fibrillation (VF)/ VT; 4: 3-5 episode of VF/VT; 5: >5 episode of VF/VT. The score of a 
particular heart was the value of the most severe type of arrhythmias exhibited during of 
10 min reperfusion. 
3.2.5. Other methods 
Isolation of cardiomyocytes and intracellular Ca2+ imaging have been described in the 
Materials and Methods in Chapter 2.  
3.2.6. Drugs and chemicals 
Type 1 collagenase, protease XIV, 2-DOG, PAG, BCA, NaHS, 5-HD, and N, N-
dimethyl-p-phenylenediamine sulphate, FeCl3 and trypan blue dye were purchased 
from Sigma Chemical Co, USA. Glibenclamide was obtained from Tocris Cookson Ltd, 
UK. HMR-1098 was a generous chased from Molecular Probes Inc. USA. 
Chelerythrine and BSM were from Calbiogift from Aventis Pharma Deutschland GmbH 
(Frankfurt, Germany). Fluo-3 was purchem. All chemicals were dissolved in distilled 
water except Fluo-3/AM, chelerythrine and BSM, which were dissolved in DMSO at a 




3.3.1. NaHS preconditioning (SP) attenuated ischemia/reperfusion-induced 
arrhythmias 
To determine whether SP is able to produce a cardioprotective effect on cardiac rhythm, 
I measured ECG in isolated rat hearts. Like numerous previous researchers, I utilized 
NaHS as a soluble H2S donor drug. Previous studies have shown that the actual amount  
of H2S generated in such solutions is about 33% of the amount of NaHS (Reiffenstein et 
al., 1992). As such NaHS (100 μM) is likely to produce approximately 33 μM H2S, 
which is well within the physiological concentration range in, for example, rat plasma 
(Zhao et al., 2001).  
Figure 3-1B & 3-1C show that low-flow ischemia/reperfusion induced severe 
arrhythmias in the vehicle preconditioning (VP) group. Both the duration of arrhythmias 
(VP:78.2±19.6 s vs SP:8.8±4.7 s, n=6, P<0.01) and the arrhythmia scores (VP:3.6±0.2 
vs SP: 0.5±0.4, n=6, p<0.001) during the 10 min reperfusion period were significantly 
decreased in the SP group.  These data suggest that SP protects the heart against 





Figure 3-1. Effect of (NaHS preconditioning) SP and (Ischemic preconditioning) IP on cardiac rhythm 
in the isolated perfused rat heart during ischemia/reperfusion. A, Experimental design. Solid fields: low 
flow perfusion with Krebs solution at a perfusion rate of 0.5 ml/min; open fields: Krebs solution at perfusion 
rate of 13 ml/min; slashed fields: Krebs solution with 100 μM NaHS. 2 mM PAG or 1 mM BCA was 
administered with/without NaHS 15 min before and during 3 cycles of IP. B & C, SP significantly decreased 
the duration of arrhythmias (B) and arrhythmia scores (C) during reperfusion compared to those in the 
control group. Mean±SEM; n=6, **P<0.01; ***P<0.001 vs VP. D & E, Role of endogenous H2S in the 
cardioprotection of IP on ischemia/reperfusion-induced arrhythmias. Co-administration of NaHS reversed 
the effects of PAG and BCA. Mean±SEM; n=5-8, *P<0.05 vs VP, +P<0.05, ++P<0.01 vs IP,  #P<0.05, 
##P<0.01 vs PAG+IP or BCA+IP.  
  
66
3.3.2. Effect of SP on cell viability and morphology subjected to ischemia 
solution 
To further substantiate the cardioprotective effect of H2S, I also assessed the 
concentration-dependent effect of NaHS on cell viability and morphology in isolated rat 
ventricular myocytes which were exposed to ischemia solution. As shown in Figure 3-
2B, preconditioned with 3 cycles of different concentrations of NaHS (1 μM, 10 μM, 
100 μM and 1 mM), the percentage of non-blue cells following ischemia increased in a 
concentration dependent manner. This effect was significantly greater than that of the 
VP group at an NaHS concentration of 10 μM and the maximum protective response 
was observed at a concentration of 100 μM NaHS (VP: 32.6±2.1%, 10 μM NaHS: 
45.9±2.3%, 100 μM NaHS: 47.9±2.2%,  all n=7; Figure 3-2B).  
To compare the responses in terms of myocyte viability and cell shape, the rod-
shaped cells were counted 10 min into the reperfusion period. As shown in Figure 3-2C, 
treatment with NaHS at 10 μM and 100 μM resulted in a greater percentage of rod-
shaped cells per the total number of cells than that detected in the VP group (VP: 













Figure 3-2. Effects of SP and IP on cell viability and morphology of ventricular myocytes. A, 
Experimental design. Solid fields: simulated ischemia solution (glucose-free Krebs solution containing 
10 mM 2-DOG and 10 mM Na2S2O4, pH6.6); open fields: fresh DMEM solution; slashed fields: 
DMEM solution containing different concentrations of NaHS. 2 mM PAG or 1 mM BCA was given 15 
min before and during 3 cycles of IP. B, concentration-dependent effect of SP on cell viability. Non-
blue cells are live cells. Mean±SEM; n=7 cultures of ≈500 cells each. ++P<0.01, +++P<0.001 vs VP. C, 
Concentration-dependent effect of SP on cell morphology. Rod-shaped cells per total cells counted. 
Mean±SEM; n=7 cultures of ≈500 cells each. +P<0.05, ++P<0.01 vs VP. D & E, Effects of IP on 
percentage of non-blue cells (D) and rod-shaped cells (E) in the presence and absence of PAG or BCA. 
Mean±SEM, n=6-18 cultures of ≈500 cells each. **P<0.01 vs VP, +P<0.05 vs IP.  
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3.3.3. Effect of SP on electrically-induced [Ca2+]i transients of the 
ventricular myocytes  subjected to ischemia solution.  
 To determine the functional status of the cells, electrically-induced [Ca2+]i transients 
before, during and after ischemia were determined. As shown in Figure 3-3A and 3-3B, 
electrically-induced [Ca2+]i transients were significantly (p<0.001) decreased after 
ischemia/reperfusion (25.8±3.0%, n=25). These results are in agreement with the effects 
of metabolic inhibition or hypoxia as reported in a previous study (Seki and MacLeod, 
1995). Like the change in cell viability, the decrease in [Ca2+]i transients during 
reperfusion were also significantly attenuated by SP (90.4± 4.6%; n=25; Figure 3-3A & 
3-3B). These results suggest that cell function was significantly improved by SP.  
3.3.4. Effects of IP on cardiac rhythm, cell viability and electrically-induced 
[Ca2+]i transients in the presence and absence of H2S synthase inhibitors 
This series of experiments was designed to determine whether endogenous H2S 
contributes to the cardioprotection of IP. PAG or BCA were administered as shown in 
Figure 3-1A. Perfusion with PAG or BCA alone for 40 min had no effect on cardiac 
rhythm (i.e. arrhythmia score and duration were 0). As shown in Figure 3-1D & 3-1E, 
IP significantly decreased the duration of cardiac arrhythmias (VP: 111.4±20.3, n=8; IP: 
41.4±9.5; n=5, p<0.05; Figure 3-1D) and the arrhythmia scores (VP: 3.5±0.3, n=8; IP: 




Figure 3-3. Effect of SP and IP on electrically-induced [Ca2+]i transients in the single ventricular 
myocytes.  Experimental procedures used were the same as those in Figure 2-2A. A, Representative tracings 
of electrically-induced [Ca2+]i transients in the VP, SP and IP groups. B, Group results showing the 
amplitudes of electrically-induced [Ca2+]i transients before and 10 min after reperfusion.  Values are 
mean±SEM; n=25. ***P<0.001 vs the value in the control (Con) group; +++P<0.001 vs the value in the VP 
group. C, Effect of IP on electrically-induced [Ca2+]i transients in the presence and absence of PAG or BCA. 




PAG or 1 mM BCA (Teague et al, 2002) 15 min before and during IP) increased the 
duration of arrhythmias (PAG: 82.4±8.2, n=6; BCA:107.4±7.8, n=5; p<0.05; Figure 3-
1D) and the arrhythmia scores (PAG: 2.75±0.2, n=6; BCA:3.2±0.4, n=5; p<0.05; Figure 
3-1E) in the IP group. Co-administration of 100 μM NaHS abolished these effects, 
suggesting that the effects of PAG and BCA were most probably secondary to a 
decrease in endogenous H2S. Taken together, these data suggest that myocyte 
endogenous H2S production may be decreased during ischemia and IP may attenuate 
this effect.  
        To further confirm whether the cardioprotection associated with IP is mediated by 
endogenous H2S, cell viability and electrically-induced [Ca2+]i transients were used as 
markers. Neither PAG or BCA alone affected cell viability (Control: 69.2±3.2%, PAG: 
63.4±2.4%, BCA: 65.1±1.7%, all n=5) or morphology (Control: 62.8±1.2%, PAG: 
60.3±1.8%, BCA: 59.2±1.2%, all n=5). The percentage of non-blue cells and rod-
shaped cells at 10 min into reperfusion in the IP group was significantly higher than that 
of the VP group (Figure 3-2D & 3-2E). Both PAG and BCA reversed the 
cardioprotection due to IP on cell viability and morphology. I also tested whether 
inhibition of endogenous H2S formation with PAG or BCA reversed the 
cardioprotection of IP on cell function by observing the amplitude of electrically-
induced [Ca2+]i transients during 10 min of reperfusion. Figure 3-3A & 3-3C show that 
the amplitudes of electrically-induced [Ca2+]i transients induced by IP were significantly 
higher than those in the VP group (VP: 20.2±3.8%; IP: 70.0±3.5%; n=26; p<0.001). 
Both PAG and BCA reversed the increased amplitudes in the IP group (PAG: 
34.8±3.6%, n=19; BCA: 37.8±4.6%; n=10, p<0.001; Figure 3-3C), but by themselves 
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did not affect electrically-induced [Ca2+]i transients in the VP group. Therefore, taken 
together, these data suggest that endogenous H2S production is likely to contribute to 
the cardioprotection caused by IP. 
 
 
Figure 3-4. Effect of IP and SP on cell viability and electrically-induced [Ca2+]i transients in rat 
ventricular myocytes in the presence and absence of PKC inhibitors. A, Experimental design. 
Chelerythrine (1 μM) or BSM (100 nM) was administrated 5 min before and during 3 cycles of IP, SP and 
VP. B, Group results of cell viability. Values are presented as non-blue cells per total myocytes counted. All 
values are mean±SEM; n=7 cultures of ≈500 cells each. *P<0.05, **P<0.01 vs VP, +P<0.05 ++P<0.01 vs IP 
or SP. C, Group results of the amplitudes of electrically–induced [Ca2+]i transient. All values are 




3.3.5. Effects of IP and SP on cell viability and electrically induced [Ca2+]i 
transients in the presence and absence of PKC inhibitors 
The goal of this series of experiments was to probe the mechanism(s) involved in the 
cardioprotection conferred by IP and SP. To determine whether PKC is involved in 
cardioprotection induced by IP and SP, two specific PKC inhibitors, chelerythrine (1 
μM) and BSM (100 nM) (Kawamura et al., 1998), were used. Either Chelerythrine or 
BSM were given 5 min before as well as during preconditioning. As shown in Figure 3-
4B & 3-4C, chelerythrine or BSM alone had no significant effect on cell viability or 
function in the VP group. However, both drugs significantly reversed the 
cardioprotective effect of IP and SP on cell viability (IP: 40.5±3.0%; Chelerythrine: 
30.1±3.6; BSM: 30.6±1.7; all n=7; p<0.05). Similarly, the improved cell functions in 
the IP and SP groups were also attenuated by the chelerythrine and BSM (Figure 3-4C). 
The amplitudes of electrically-induced [Ca2+]i transients were decreased from 
74.2±4.2% (n=26) in the IP group to 37.2±3.6% in the chelerythrine group (n=28, 
p<0.001) and 35.6 ±5.7% (n=13) in the BSM group and decreased from 97.3±5.8% 
(n=38) in the SP group to 38.0±3.3% in the chelerythrine group (n=25, p<0.001) and 
58.2 ± 4.7% in the BSM group (n=18, p<0.001).  
 
3.3.6. Effects of IP and SP on cell viability and electrically induced [Ca2+]i 
transients in the presence and absence of KATP channel blockers 
To determine the involvement of KATP channels in the cardioprotection induced by SP 
and IP, either glibenclamide (10 μM), a non-selective KATP channel blocker, 5-HD (100 
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μM), a selective mitoKATP channel blocker or HMR-1098 (30 μM), a selective sarcKATP 
blocker, were administered 5 min before and during preconditioning (Chen et al., 2003). 
The experimental procedures are shown in Figure 3-5A. As shown in Figure 3-5B & 3-
5C, all three drugs alone did not affect cell viability and function in the VP group. Fig 
3-5B shows that glibenclamide significantly reduced cell viability in both the IP and SP 
groups (IP: 44.9±3.1%, n=15; vs glibenclamide+IP: 32.2±3.7, n=9; p<0.05; SP: 
Figure 3-5. Effect of IP and SP on cell viability and electrically-induced [Ca2+]i transients of rat 
ventricular myocytes in the presence and absence of KATP channel blockers. A. Experimental procedure. 
Glebenclamide, 5-HD and HMR-1098 were given 5 min before and during VP, SP or IP. B, Group results of 
cell viability. Values are presented as non-blue cells per total myocytes counted. Mean±SEM; n=8-18 
cultures of ≈500 cells each. **P<0.01 vs VP, +P<0.05 vs IP or SP. C, Group results of the amplitudes of 
electrically–induced [Ca2+]i transient. Mean±SEM; n=12-40, ***P<0.001 vs VP, +++P<0.001 vs IP or SP. 
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50.8±2.7%, n=18; vs glibenclamide+SP: 34.1±2.7%; n=8; p<0.05). Similar results were 
also obtained in cell function using electrically-induced [Ca2+]i transients as the end-
point (Figure 3-5C). Glibenclamide significantly attenuated the increased amplitudes of 
electrically-induced [Ca2+]i transients in the IP (IP: 67.9±3.5%, n=37; vs 
Glibenclamide+IP: 37.4±3.1%; n=40; p<0.001) and SP (SP: 81.9±3.7, n=12; vs 
Glibenclamide+SP: 39.4±4.1; n=32; p<0.001) groups. These data suggest that KATP 
channel is involved in the cardioprotection conferred by both IP and SP.  
5-HD and HMR-1098 were further employed to determine the involvement of 
mitoKATP or sarcKATP channels in the cardioprotection of IP and SP. HMR-1098 
significantly decreased the cell viability (IP+HMR: 30.9±4.6%; n=8; SP±HMR: 
35.2±4.7%; n=8, p<0.05; Figure 3-5B) and the amplitudes of electrically-induced 
calcium transients (IP+HMR: 23.1±2.2%, n=21; SP+HMR: 23.0±3.3%%, n=12; Figure 
3-5C) in both IP and SP group. However, 5-HD only significantly attenuated the 
cardioprotection of IP (cell viability: 29.6±2.8%, n=8; [Ca2+]i transients: 30.1±4.2%, 
n=29), but had no significant effect on these parameters in the SP group (cell viability: 
49.7±1.6%, n=8; [Ca2+]i transients: 75.9±5.4, n=12, Figure 3-5A & 3-5B). These data 
suggest that unlike the mechanism of IP, sarcKATP channel, but not the mitoKATP 







3.3.7. Effects of H2S synthesis inhibitors, IP and SP on H2S levels in the 
culture medium of cardiac myocytes 
I first observed whether PAG and BCA treatment for 40 min inhibited endogenous H2S 
production in these experiments. As shown in Figure 3-6B, both PAG and BCA 
significantly decreased H2S production by 78.8±7.1 % (n=5) and 60.4±7.6% (n=5), 
respectively.  
Figure 3-6. Effect of CSE inhibitors, ischemia, IP and SP on H2S production in the rat ventricular 
myocytes. A, Experimental design. B, PAG and BCA decreased endogenous H2S production. Mean±SEM; 
n=5. ***P<0.001 vs Control (Con). C, IP and SP attenuated the effect of ischemia on endogenous H2S 
production. Mean±SEM; n=5-10. ***P<0.001 vs Control (Con), +P<0.05 vs VP.  
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To further investigate the hypothesis that endogenous H2S may mediate the 
cardioprotection associated with IP, H2S concentration in cell culture medium after 9 
minutes of ischemia was determined. The experimental procedures are shown in Figure 
3-6A and described in Methods. As shown in Figure 3-6B, ischemia for 9 min (VP 
group) significantly decreased (23.7±6.9 % (n=10, p<0.001) H2S level in the VP group, 
suggesting that endogenous H2S production is markedly decreased during ischemia. 
Interestingly, preconditioning with three cycles of ischemia or NaHS (100 μM) 
significantly attenuated the inhibitory effect of ischemia on H2S production (IP: 
49.6±9.5%; SP: 59.5±8.6%; n=5, p<0.05 vs ischemia group). These data suggest that 





In the present study, I have observed a cardioprotective effect of exogenous application 
of NaHS. I observed that preconditioning with 100 μM NaHS attenuated arrhythmias in 
the isolated Langendorff-perfused heart (subjected to low-flow ischemia insults), 
increased cell viability and improved cell function in cardiac myocytes during 
ischemia/reperfusion. Our data clearly suggest that, at physiological concentrations, H2S 
produces a cardioprotective effect.  
 Subsequently, I examined the potential role of endogenous H2S in 
cardioprotection due to IP. Treatment of cardiac myocytes with either PAG or BCA 
markedly decreased endogenous H2S production and significantly attenuated the 
protective effect of IP in the isolated rat heart and cardiac myocytes. Moreover, I also 
observed that H2S production was decreased when ventricular myocytes were subjected 
to ischemia. Both IP and SP significantly attenuated the inhibitory effect of ischemia on 
H2S production. Taken together, our data provide the first evidence that endogenous 
H2S plays an important role in protecting heart function. 
 Ischemia/reperfusion-induced arrhythmias originate from a series of complex 
cellular and humoral reactions. The primary causes are considered to be the endogenous 
metabolites produced and accumulated in the myocardium during reperfusion. These 
various metabolites include, for example, reactive oxygen species (ROS), calcium, 
thrombin and platelet activating factor. H2S may protect the heart against arrhythmias 
by scavenging ROS (Geng et al., 2004a) and opening KATP channel (Zhao et al., 2001) 
which reduce calcium influx and shortens action potential duration (APD). During 
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ischemia, H2S production was markedly decreased. So this effect may increase harmful 
chemical substances such as ROS, which may, in turn, modulate cellular 
electrophysiology causing the complex changes at the level of ion channels and induce 
the arrhythmias. After preconditioning, both IP and SP could stimulate the heart to 
produce more endogenous H2S and therefore protect the hearts. Blockade of 
endogenous H2S synthesis increased both the duration of ischemia/reperfusion-induced 
arrhythmias and the severity of the arrhythmias. Thus, these data suggest that the 
endogenous H2S system may mediate the cardioprotection induced by ischemic 
preconditioning.  
In the present study, I also investigated the signaling mechanism underlying the 
cardioprotection of SP and IP. Both chelerythrine and BSM, (two specific PKC 
inhibitors) attenuated the protective effect of SP and IP, thereby suggesting that PKC 
may mediate the cardioprotection caused by both SP and IP. This is consistent with a 
previous observation that PKC plays an important role in mediating IP (Gross and Peart, 
2003). During IP, PKC stimulation is secondary to activation of Gq or Gi/o protein 
coupled receptor (Eisen et al., 2004). The mechanism(s) by which PKC is activated 
during SP is unclear. However, an effect to open of KATP channels may be involved. 
This is supported by previous findings which showed that H2S opens KATP channels in 
vascular smooth muscle cells (Zhao et al., 2001). Indeed, activation of PKC and KATP 
channels may be co-dependent (Baxter et al., 1995; Gross and Peart, 2003). Since 
protection provided by direct KATP channel openers may be abolished by PKC 
antagonists and vice versa, which implies that activation of PKC and KATP channels are 
both codependent and necessary for cardioprotection (Gaudette et al., 2000). Additional 
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experiments are needed to determine whether opening of KATP channels is an event 
upstream of PKC activation.  
KATP channels are well known to play an important role in the cardioprotection 
induced by IP. However, the subtype of KATP channel which confers cardioprotective 
activity is still controversial. Since the first evidence of a role of the KATP channels in 
acute IP is presented (Gross and Auchampach, 1992) in the canine heart, results 
obtained in a number of studies using a variety of different models and species 
supported that the possibility sarcKATP channels triggered or mediated the 
cardioprotective effects of IP. Thus, IP and KATP channel openers shorten action 
potential duration (APD) (Noma, 1983; Tan et al., 1993), whereas KATP channel 
blockers attenuate the effect of IP on APD shortening (Cole et al., 1991; Yao and Gross, 
1994). More evidence for the involvement of sarcKATP channel was provided by Suzuki 
and colleagues (Suzuki et al., 2002). They demonstrated that cardioprotection due to IP 
was blocked by HMR-1098 (a putative sarcKATP channel blocker) but not by 5-HD. 
However, Sasaki et al found MCC-134, a novel pharmacological agent which opens 
sarcKATP channels and blocks mitoKATP channels, attenuated the effects of IP. These 
data suggest that the sarcKATP channel may not be totally accountable for the protective 
effects afforded by IP.  In the present study, I found that the subtypes of KATP channels 
involved in the cardioprotection of IP and SP may differ. I observed that various KATP 
channel blockers, including glibenclamide, 5-HD and HMR-1098, attenuated the 
cardioprotection of IP, which suggests that both sarcKATP and mitoKATP are involved. 
However, selective blockade of mitoKATP channels with 5-HD had no effect on the 
protective effect of SP on cell viability and cell function, whereas glibenclamide and 
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HMR-1098 significantly attenuated this effect. Thus, these data suggested that 
sarcKATP, but not mitoKATP, may mediate the cardioprotection of SP.  
Opening of the sarcKATP channel induced by SP would be expected to enhance 
shortening of the cardiac APD by accelerating phase 3 repolarization. Thereby 
inhibiting Ca2+ entry into the cell via L-type channels and preventing Ca2+ overload. 
Furthermore, the slowing of depolarization would also be expected to reduce Ca2+ entry 
and slow or prevent the reversal of the Na+-Ca2+ exchanger. All of these actions may 
increase cell viability via a reduction in Ca2+ overload during ischemia and early 
reperfusion.  
Both PAG and BCA have been widely used to inhibit CSE activity and 
endogenous H2S production. PAG causes an irreversible inhibition of CSE activity --- 
in vitro (Johnston et al., 1979) and in vivo (Mok et al., 2004; Porter et al., 1996; Uren et 
al., 1978), whereas BCA is a reversible inhibitor of CSE (Pfeffer and Ressler, 1967; 
Uren et al., 1978). Despite the widespread use of both PAG and BCA to inhibit H2S 
formation there is a possibility that one or both of these compounds may produce effects 
by mechanism(s) which are unrelated to inhibition of CSE. However, this possibility 
seems unlikely since neither PAG nor BCA alone significantly affected cell viability or 
heart rhythm. Furthermore, co-administration of NaHS reversed the effect of both CSE 
inhibitors that both drugs attenuated the cardioprotection of IP on cardiac rhythm, 
implying that the effects of PAG and BCA most likely result from a decrease in 
endogenous H2S formation. 
 In summary, it was demonstrated, for the first time, that endogenous H2S 
contributes to the cardioprotection conferred by IP and pharmacological 
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preconditioning with the H2S donor, NaHS confers cardioprotection. SarcKATP channel 
and PKC may be involved in the cardioprotective effect of H2S. In addition, mitoKATP 
may also be involved in the cardioprotective effect induced by IP.  
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Chapter 4   Role of hydrogen Sulfide in the Cardioprotection 
Induced by Ischemic Postconditioning 
4.1.  Introduction 
In chapter 3, it was demonstrated that endogenous H2S mediated the cardioprotection 
induced by ischemic preconditioning, and a H2S donor was an effective 
pharmacological preconditioning agent. However, ischemic preconditioning has a major 
limitation in that brief ischemia maneuver or its mimetic, which can trigger 
pharmacological preconditioning, has to be applied before the index ischemia insult. 
This has lead to the introduction of the concept of ischemic postconditioning (IPostC) 
by Na’s (Na et al., 1996) and Vinten-Johansen’s groups (Zhao et al., 2003). IPostC is 
defined as the phenomenon where rapid intermittent interruptions of blood flow in the 
early phase of reperfusion resulted in a reduced myocardial injury (Zhao and Vinten-
Johansen, 2006). This maneuver has produced promising protection against ischemia-
reperfusion injury in mice (Kin et al., 2005), rats (Kin et al., 2004), rabbits (Yang et al., 
2004b), dogs (Zhao et al., 2003) and in human patients (Staat et al., 2005).  
Exogenous H2S was shown to activate several pro-survival kinases such as 
ERK1/2 (Yang et al., 2004a; Yang et al., 2006; Zhi et al., 2007), Akt (Hu et al., 2007d) 
and PKC (Pan et al., 2007), which are the mediators of IPostC. Although the complete 
signaling mechanisms of H2S remains unclear, the general understanding on the 
cardioprotective effect of H2S up to date has led us to hypothesize that endogenous H2S 
may contribute to the protective effect of IPostC. As such, the aim of our study was to 
examine whether endogenous H2S plays a role in mediating the IPostC via activation of 
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pro-survival kinases. In addition, the role of exogenous H2S to serve as a potential 
candidate to trigger pharmacological postconditioning was also studied. 
4.2. Materials and methods 
4.2.1. Measurement of cardiodynamic functions 
Cardiodynamic parameters were measured with a pressure transducer connected to a 
PowerLab system (ADInstruments, Australia).  An incision was made in the left atrium 
and a fluid-filled latex balloon connected to the pressure transducer was inserted and 
positioned in the left ventricular cavity for continuous assessment of cardiodynamic 
function. The balloon was initially inflated to an end-diastolic pressure of 5 – 10 mmHg 
and thereafter the balloon volume was held constant.  The hearts were perfused at a 
constant flow rate of 12 ml/min. Cardiodynamic data were analyzed using a Data 
Acquisition System (PowerLab System, AD Instruments, Australia). Left ventricular 
end diastolic pressure (LVeDP) was represented by the minimum pressure recorded 
during diastoles, left ventricular developed pressure (LVDP) was calculated as the 
difference between left ventricular systolic pressure and left ventricular diastolic 
pressure, contractility (+dP/dt) was represented by the maximum gradient during 
systoles and compliance (-dP/dt) was represented by the minimum gradient during 
diastoles.  
4.2.2. Measurement of myocardial infarction size 
Regional ischemia was induced by ligating the left main coronary artery (LAD) for 40 
minutes. The ligation was released during the 2 h reperfusion. After 2 h reperfusion, the 
infarct–risk volume ratio was determined. As described previously (Hausenloy et al., 
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2005),  the heart was stained by slowly infusing 1 ml of Evan’s blue (3% w/v in 
phosphate-buffered saline) via the aorta, followed by perfusion with Krebs bicarbonate 
buffer to wash out unbound stains. The heart was then immediately removed from the 
perfusion apparatus, weighed, and stored overnight at −20°C. The frozen heart was 
thereafter cut into five or six transverse sections (approximately 2 mm in thickness) 
across the long axis, stained with 1% TTC in phosphate buffer (pH 7.4) for 20 min at 
37°C, and then fixed in 10% formalin overnight. The size of the myocardial infarction 
(appearing as pale color) was quantified by ImageJ (1.32j, National Institutes of Health, 
USA) and calculated as percentage of area at risk which is the area not stained by 
Evan’s blue. 
4.2.3. Western blot analysis 
After 1 hr reperfusion, the ventricular tissues of the heart which had undergone global 
ischemia were freeze-clamped in liquid nitrogen and stored at -80 ºC for further 
analysis. Phosphorylation state of Akt and eNOS, and translocation of PKCα, PKCδ and 
PKCε, was assessed with standard western immunoblotting. Briefly, 25 mg of tissues 
were minced and homogenized in ice-cold lysis buffer containing (mM) 25 Tris·HCl pH 
7.5, 150 NaCl, 5 EDTA, 10 NaF, 1 Na3VO4, 1% NP-40 and 0.4% deoxycholic acid 
supplemented with protease inhibitor cocktail tablet (Roche Diagnostics, Penzberg, 
Germany). A cell fractionation technique was adopted from the literature (Weber et al., 
2005).  Homogenates were centrifuged at 1,000xg for 10 min. The cytosolic fraction of 
the proteins were obtained by collecting the supernatant and centrifuged at 16,000xg to 
maximize protein extraction. The membrane fraction was obtained by treating the pellet 
with lysis buffer supplemented with 1% Triton-X followed by centrifugation at 
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16,000xg. Protein concentrations were determined using the modified Lowry method. 
Proteins were denatured with SDS-sample buffer and epitopes were exposed by boiling 
the protein samples at 100 oC for 5 min. Equal amount of proteins were loaded and 
separated by electrophoresis on 12% SDS-polyacrylamide gel and transferred to 
nitrocellulose membrane. The membrane was first probed with the primary antibody 
that recognizes phospho-Akt (p-Akt, serine 473), total Akt, phospho-endothelial NO 
synthase (p-eNOS, serine 1117), total eNOS, PKCα, PKCδ or PKCε and then with a 
horseradish peroxidase-conjugated goat-anti-rabbit IgG secondary antibody. 
Immunoreactivity was detected using the enhanced chemiluminescence method. Protein 
levels were normalized to the VPostC group. 
4.2.4. Measurement of H2S-synthesis enzymes activity 
Tissue H2S production rate was measured essentially as described previously (Webb et 
al., 2008; Yong et al., 2008b). Briefly, a snap-frozen 100mg of rat ventricular tissues 
from VPostC, IPostC and IPostC+PAG groups were homogenized in 1 ml of 100 mM 
potassium phosphate buffer, pH 7.4. The assay mixtures (500 µl) contained 460 µl of 
tissue homogenate, 10 mM L-cysteine, and 2 mM pyridoxal 5’-phosphate. Incubation 
was carried out in tightly sealed Eppendorf vials. After incubation (37ºC, 30 min), zinc 
acetate (1% w/v, 250 µl) was added to trap the generated H2S followed by 
trichloroacetic acid (10% w/v, 250 µl) to stop the reaction. Next, N,N-dimethyl-p-
phenylenediamine sulfate (20 mM, 133 µl) and FeCl3 (30 mM; 133 µl) was added and 
centrifuged under 14,000 g. After 10 min, absorbance at 670 nM of 200 µl aliquots of 
the supernatant was determined. The H2S concentration of samples was calculated using 
a calibration curve of NaHS (3.125 – 200 µM), and the results were expressed as 
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nanomoles of H2S produced per milligram of soluble protein per 30 min. Protein was 
determined with NanoDrop Spectrophotometer (NanoDrop technology, ND-1000, DE, 
USA). 
4.2.5. Experimental Protocol 
Isolated rat hearts were perfused and stabilized for at least 20 min before data recording. 
Global ischemia was mimicked by stopping the perfusion of Krebs bicarbonate buffer, 
i.e. perfusion rate = 0 ml/min. The hearts were randomly divided into nine groups 
according to the perfusion protocol as shown in Fig. 1a, 2a, 5a, 9a and 10a. Vehicle 
postconditioning group (VPostC) and ischemic postconditioning group (IPostC) serve 
as the negative and positive controls in this study. In VPostC and IPostC groups, hearts 
experienced 20 minutes equilibration followed by 40 min global ischemia. Upon 
reperfusion, IPostC hearts were treated with 6 cycles of 10 s reperfusion and 10 s no 
flow ischemia (total intervention time of 2 min) whereas VPostC hearts did not receive 
any additional treatment. In IPostC+PAG group, hearts were pre-treated with 2 mM 
PAG, a CSE inhibitor, 15 min before, during and 2 min after ischemia treatment (Fig. 
1a & 2a). Two protocols of H2S postconditioning were adopted: SPostC group hearts 
were treated with 6 cycles of 10 s reperfusion and 10 s 100 μM NaHS, a H2S donor, 
intermittently whereas SPostC2 group hearts were treated with 100 μM NaHS for two 
minutes continuously (Figure 4-5). NaHS treatments were performed by directly 
injecting 100 μM NaHS into perfusing Krebs bicarbonate buffer to avoid flow 
interruption caused by switching of stopcocks.  In four parallel groups (SPostC-LY, 
SPostC2-LY, SPostC-CHE and SPostC2-CHE), hearts were treated with 15 μM 
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LY294002 (PI3K/Akt inhibitor), or 10 μM chelerythrine (PKCs inhibitor) 10 min 
before, during and 5 min after ischemia insults (Fig. 9a & 10a).  
4.2.6. Other methods 
Isolated prefused rat heart preparation and H2S concentration and its generating enzyme 
activity have been described in the Materials and Methods in Chapter 2.  
4.2.7. Statistical analysis 
All values were expressed as mean ± SEM. Cardiodynamic data were assessed with 
one-way ANOVA followed by Tukey’s post hoc test. Immunoreactivity of each protein 
of interest was normalized to VPostC and compared among the groups by ANOVA and 
subsequent Newman-Keuls post hoc test. Differences were considered statistically 
significant when p<0.05. 
4.2.8. Drugs and chemicals 
NaHS and D-L-propargylglycine (PAG) were purchased from Sigma Chemical Co, 
USA. Chelerythrine chloride and LY294002 were purchased from Calbiochem, 
Darmstadt, Germany. Polyclonal anti-phospho-Akt rabbit IgG and polyclonal anti-total-
Akt rabbit IgG were purchased from Cell Signaling Technology Inc, USA. Polyclonal 
anti-PKCε rabbit IgG antibody was purchased from Santa Cruz Biotechnology, Santa 
Cruz, CA. Chelerythrine chloride and LY294002 was dissolved in dimethyl sulphoxide 
(DMSO) and added to the Krebs bicarbonate buffer such that the final DMSO 






4.3.1. Activity of H2S-synthesis enzymes in ischemia/reperfusion with and 
without IPostC treatment 
The experimental protocols are shown in Figure 4-1A. H2S-generating enzyme 
activities in the heart tissues were measured at the end of 6 cycles of postconditioning 
treatment in IPostC group or after 2 min of reperfusion in VPostC group. As shown in 
Figure 4-1B, H2S-synthesis enzyme activity was significantly decreased in VPostC 
group, suggesting that ischemia may inhibit endogenous H2S production. This is 
consistent with our previous findings that ischemia decreases H2S production in isolated 
cardiomyocytes (Bian et al., 2006; Pan et al., 2006). However, the decreased enzyme 
activity was dramatically reversed and enhanced by IPostC, suggesting that IPostC 
treatment can strongly stimulates the production of endogenous H2S, which may serve 
as a mediator for the cardioprotective effects of IPostC.   
It was also found that the effect of IPostC on H2S-generating enzyme activity was 
blocked by PAG (Figure 4-1B), confirming that PAG can serve as an inhibitor of CSE 
in our experimental model. To test whether PAG can be safely used in the functional 
studies, I also examined its effect on cardiodynamic function in the isolated rat hearts. 
As shown in Figure 4-1C & 4-1D, administration of PAG (2 mM) for 40 min did not 
impair LVDP. PAG was therefore employed in the following experiments to test the 










Figure 4-1 Activity of H2S-generating enzymes with and without IPostC and the effect of PAG on 
cardiodynamic function. (a) Experimental protocols. Open field: Krebs solution; solid field: no flow 
ischemia. PAG, a H2S synthesis inhibitor, was given 15 min before, during and 2 min after ischemia treatment. 
(b) Effect of IPostC on the activity of H2S-synthesis enzymes with and without IPostC. Mean data showing the 
H2S production produced by the H2S-generating enzyme in the homogenates of rat ventricular tissue in the 
presence of substrate and co-factors. 0 time group serves a negative control, representing the start of the 
experiment when no H2S is produced. The next four bars show the production of H2S after 30 min. All values 
are mean ± S.E.M. (n=8), #p<0.05 VPostC vs. control, **p<0.01 VPostC vs. IPostC, †p<0.05 IPostC vs. 
IPostC+PAG.   (c-d) Effect of PAG on cardiodynamic function. (c) Representative tracings showing the 
mechanical performance of isolated heart during perfusion of 2mM PAG for 40 min (lower panel) as 
compared to Kreb’s solution only (upper panel). (d) Mean data of LVDP showing that 2 mM PAG alone did 




4.3.2. Role of endogenous H2S in the cardioprotection induced by IPostC 
Cardiodynamic function was measured to test the involvement of endogenous H2S in 
the cardioprotection induced by IPostC. The experimental protocols are shown in Figure 
4-2A and described in the Materials and Methods. As shown in Fig. 4-2B & 4-2C, 
IPostC significantly protected the heart by resuming the functional performance after 
ischemia as compared to VPostC when assessed with LVeDP, LVDP and ±dP/dt. 
Inhibition of endogenous H2S synthesis with 2 mM PAG from 15 minutes before up to 
2 minutes after ischemia significantly diminished the cardioprotective effect of IPostC 
by elevating LVeDP and reducing both LVDP and +dP/dt. However, no significant 
change in –dP/dt was observed, implying a minor role played by endogenous H2S in 
heart relaxation.  
4.3.3. Role of endogenous H2S in the activation of PKC isoforms triggered 
by IPostC 
PKC is an important trigger/mediator in the cardioprotection induced by IPostC (Philipp 
et al., 2006; Zatta et al., 2006). The PKC family consists of at least 10 isoforms, among 
which PKC-α, ε and δ are the prominent isoforms expressed in the heart (Mackay and 
Mochly-Rosen, 2001b). I therefore examined whether endogenous H2S mediates the 
activation of these three PKC isoforms during IPostC. As shown in Fig. 4-3, 
translocation of different PKC isoforms (α, δ and ε) from cytosol to membrane was 
observed in IPostC treatment group, indicating IPostC stimulates these PKC isoforms. 
Inhibition of endogenous H2S synthesis with PAG significantly reversed the 
translocation of PKCα and PKCε but not PKCδ (Fig. 4-3). These data suggest that 
endogenous H2S played a part in IPostC-triggered activation of PKCε and PKCα. 
  
91
Figure 4-2 Effect of IPostC on cardiodynamics in the presence and absence of PAG, a H2S synthesis 
inhibitor. (a) Experimental protocols. Open field: Krebs solution; solid field: no flow ischemia. PAG was given 
15 min before, during and 2 min after ischemia treatment. (b) Representative tracings showing the mechanical 
performance of isolated rat hearts during 40 minutes ischemia and subsequent one hour reperfusion in VPostC, 
IPostC and IPostC+PAG groups. (c) Mean data of left ventricular end-diastolic pressure (LVeDP) (upper left 
panel), left ventricular developed pressure (LVDP) (upper right panel), contractility (+dP/dt) (lower left panel) 
and compliance (-dP/dt) (lower right panel). All values are mean ± S.E.M. (n=6), *p<0.05 VPostC vs. IPostC, 
#p<0.05 IPostC vs. IPostC+PAG.    
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Figure 4-3. Activation of PKC isoforms by 
IPostC cardiodynamics in the presence and 
absence of PAG, a H2S synthesis inhibitor. 
Representative Western blots (upper panels) 
and the intensity ratio of membrane to cytosolic 
fraction (lower panels) of PKCα (a), δ (b) and ε 
(c). Data are shown in Mean ± S.E.M. Ratios 
are normalized to VPostC values (n=3-5). 
*p<0.05 VPostC vs. IPostC, #p<0.05 IPostC vs. 




4.3.4. Role of endogenous H2S in the activation of Akt and eNOS triggered 
by IPostC 
Since IPostC was shown to trigger cardioprotection partly via activation of pro-survival 
kinase Akt (Tsang et al., 2004; Zhu et al., 2006) and eNOS (Tsang et al., 2004), I 
further examined whether inhibition of endogenous H2S production could reverse 
phosphorylation of Akt and eNOS upon IPostC treatment. As shown in Fig. 4-4, IPostC 
significantly induced phosphorylation of Akt (Fig. 4-4A) and eNOS (Fig. 4-4B). This is 
consistent with the previous findings from other groups (Tsang et al., 2004; Zhu et al., 
2006). However, inhibition of endogenous H2S synthesis with PAG failed to attenuate 
IPostC-induced phosphorylation of Akt (Fig. 4-4A) and eNOS (Fig. 4-4B), suggesting 





Figure 4-4. Activation of Akt and eNOS by IPostC in the presence and absence of PAG, a H2S 
synthesis inhibitor. Representative Western blots (upper panels) and the relative intensity of phospho-
Akt/total-Akt (a) & phosphor-eNOS/total eNOS (b) showing PAG failed to abolish the IPostC induced 
activation of Akt and eNOS. Data are shown in Mean ± S.E.M. Ratios are normalized to VPostC values 





4.3.5. H2S postconditioning improves the cardiodynamic performance of 
isolated perfused rat heart after ischemia 
This series of experiments were designed to determine whether postconditioning with 
exogenous H2S was also able to produce cardioprotection. NaHS-reperfusion was used 
to substitute the six episodes of ischemia-reperfusion in IPostC. As shown in Fig. 4-5A, 
two pharmacological postconditioning protocols which were commonly adopted by 
other groups (Lu et al., 2006; Tissier et al., 2007) were used in the present study. Since 
NaHS at 100 μM exhibited the maximal cardioprotective effect from ischemia-induced 
injury in both cardiac myocytes (Pan et al., 2006) and isolated rat hearts (Hu et al., 
2007d), 100 μM was therefore chosen to oberve the cardioprotection of NaHS 
postconditioning in the following experiments. In SPostC group, hearts received  6 
cycles of 10 s reperfusion and 10 s NaHS infusion after ischemia, whereas in SPostC2 
NaHS (100 μM) was given for two minutes continuously after ischemia. Fig. 4-5B and 
4-5C showed that both SPostC and SPostC2 treatment significantly improved the 
cardiodynamics including LVeDP, LVDP and ±dP/dt during reperfusion after ischemia. 




Figure 4-5. Effect of H2S postconditioning on cardiodynamics. (a) Experimental protocols.  Open 
field: Krebs solution; solid field: no flow ischemia; slashed field: Krebs solution with 100 μM NaHS. 
(b) Representative tracings showing the mechanical performance of isolated rat hearts during 40 
minutes ischemia and subsequent 1 hour reperfusion in different groups. (c) Mean data of left 
ventricular end-diastolic pressure (LVeDP) (upper left panel), left ventricular developed pressure 
(LVDP) (upper right panel), contractility (+dP/dt) (lower left panel) and compliance (-dP/dt) (lower 
right panel). All values are mean ± S.E.M. (n=6), *p<0.05 VPostC vs. IPostC, #p<0.05 VPostC vs. 




4.3.6. H2S postconditioning limits myocardial infarct size of isolated 
perfused rat heart  
To further confirm the cardioprotective effects of SPostC, infarct size was assessed in 
VPostC, SPostC and SPostC2 groups. Hearts received SPostC and SPostC2 treatment 
displayed 71% & 72% reductions, respectively, in infarct size per area-at-risk (SPostC: 
12.7 ± 5%; SPostC2: 12.4 ± 3%) as compared with that in vehicle group (44.1 ± 5%, 
Fig. 4-6). These data confirm that H2S may serve as a possible trigger for 
pharmacological postconditioning. 
 
Figure 4-6. Effect of H2S 
postconditioning on myocardial 
infarction. (a) Representative mid-
myocardial cross sections of TTC-
stained hearts in vehicle, SPostC and 
SPostC2 groups. Dark blue area 
indicates non-ischemic area. Total area 
of white (infracted tissue) and red (viable 
myocardium) represents area-at-risk. (b) 
Mean data showing that SPostC and 
SPostC2 significantly reduced the 
myocardial infarct size as compared to 
VPostC group. All values are mean ± 




4.3.7. H2S postconditioning activates Akt, eNOS and PKC 
The signaling mechanisms underlying the cardioprotection of H2S postconditioning 
were also examined. I first determined the involvement of PKC isoforms (α, δ and ε) in 
the cardioprotection triggered by H2S postconditioning. SPostC translocated all three 
isoforms of PKC, however, SPosC2 only induced PKCδ activation (Fig. 4-7), implying 
that SPostC and SPostC2 may induce cardioprotection via different signaling 
mechanisms.  
Since both Akt and eNOS mediate the cardioprotection of IPostC, 
phosphorylation of Akt and eNOS was also examined. When compared to VPostC, both 
SPostC and SPostC2 treatment induced significant phosphorylation of Akt (Fig. 4-8A). 
Interestingly, SPostC2, but not SPostC, also induced the phosphorylation of eNOS (Fig. 
4-8B).  
4.3.8. Roles of Akt and PKC in the cardioprotection triggered by H2S 
postconditioning 
To further confirm the role of Akt and PKC in the cardioprotection induced by H2S 
postconditioning, specific inhibitors of PI-3-Kinase (PI3K)/Akt and PKC were 
administered in both SPostC and SPostC2 groups. As shown in Fig. 4-9 & 4-10, 
inhibition of either PI3K/Akt pathway with LY294002 (15 µM) or PKC with 
chelerythrine (10 µM) during the H2S infusion period significantly reversed the 
protective effect on contractile function in both SPostC and SPostC2 groups. These data 
suggest that activation of both PI3K/Akt and PKC pathways are essential in the 
cardioprotection induced by both SPostC and SPostC2.  
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Figure 4-8. Activation of Akt and eNOS induced by IPostC, SPostC and SPostC2. Representative Western 
blots (upper panels) and the relative intensity of phospho-Akt/total-Akt (a) & phospho-eNOS/total eNOS (b) 
showing SPostC2 stimulated both Akt and eNOS, whereas SPostC only activated Akt. Data are shown in Mean ± 
S.E.M. Ratios are normalized to VPostC values, (n=3-5). *p<0.05 vs. VPostC.    
Figure 4-7. Effect of SPostC on 
cardiodynamics upon inhibition of Akt or 
PKC. (a) Experimental protocols: H2S 
postconditioning with 6 cycles of 10 s reperfusion 
and 10 s 100 μM NaHS intermittently (SPostC). 
LY = LY294002, PI3K inhibitor; CHE = 
chelerythrine, PKC inhibitor (b) Mean data of left 
ventricular end-diastolic pressure (LVeDP) (upper 
left panel), left ventricular developed pressure 
(LVDP) (upper right panel), contractility (+dP/dt) 
(lower left panel) and compliance (-dP/dt) (lower 
right panel). All values are mean ± S.E.M. (n=5-
6), *p<0.05 SPostC vs. SPostC-LY, #p<0.05 







Figure 4-9. Effect of SPostC on cardiodynamics upon inhibition of Akt or PKC. (A) Experimental 
protocols: SPostC. LY = LY294002, a PI3K inhibitor; CHE = chelerythrine, a PKC inhibitor (B) Mean 
data of left ventricular end-diastolic pressure (LVeDP) (top left), left ventricular developed pressure 
(LVDP) (top right), contractility (+dP/dt) (bottom left) and compliance (-dP/dt) (bottom right). All values 











Figure 4-10. Effect of SPostC2 on cardiodynamics upon inhibition of Akt or PKC. (a) Experimental 
protocols: H2S postconditioning with 100μM NaHS for two minutes continuously (SPostC2). LY = 
LY294002, a PI3K inhibitor; CHE = chelerythrine, a PKC inhibitor (b) Mean data of left ventricular end-
diastolic pressure (LVeDP) (upper left panel), left ventricular developed pressure (LVDP) (upper right 
panel), contractility (+dP/dt) (lower left panel) and compliance (-dP/dt) (lower right panel). All values are 





The main objective of this study was to unveil the role of endogenous H2S in the 
cardioprotection of IPostC and to explore the feasibility of postconditioning with 
exogenous H2S to trigger cardioprotection. Cardiodynamics of isolated perfused rat 
heart and myocardial infarction were chosen as the parameter to assess the functional 
performance of the heart after ischemia. In the present study, I found that IPostC 
significantly improved the heart contractile function after ischemia. This is consistent 
with the previous findings that IPostC protects the heart from lethal ischemia 
reperfusion injury when assessed by infarct size (Darling et al., 2005; Kin et al., 2004; 
Yang et al., 2005b), cardiodynamic performance (Crisostomo et al., 2006; Fantinelli and 
Mosca, 2007; Kin et al., 2005; Zhu et al., 2006), cellular injury index (Sun et al., 2005; 
Wang et al., 2006) etc. Inhibition of endogenous H2S synthesis with PAG, an 
irreversible inhibitor of CSE, partly attenuated the cardioprotective effect of IPostC. 
More importantly, I found that IPostC treatment stimulated the activity of H2S-
generating enzymes in the early phase of reperfusion. These observations suggest a role 
for endogenous H2S in the phenomenon.   
Interestingly, inhibition of endogenous H2S synthesis with PAG did not block all 
signaling pathways stimulated by IPostC. PAG attenuated IPostC-induced translocation 
of PKCε and PKCα, but failed to affect the phosphorylation of Akt, eNOS and 
translocation of PKCδ. These data suggest a central dominant role for endogenous H2S 
in the activation of the pro-survival PKCε and PKCα, whereas activation of Akt, eNOS 
and PKCδ by IPostC might not be solely dependent on endogenous H2S. It has been 
reported that adenosine receptor activation (Philipp et al., 2006) or prolonged transient 
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acidosis during IPostC is able to induce Akt phosphorylation. These signaling 
mechanisms may act in a concerted manner to trigger Akt activation and its downstream 
target eNOS to protect heart against ischemia reperfusion injury via inhibiting opening 
of mitochondrial permeability transition pore (Tsang et al., 2004).  
In the present study, two IPostC protocols commonly used by other groups (Lu 
et al., 2006; Tissier et al., 2007) were employed to investigate whether postconditioning 
with exogenous H2S can also produce cardioprotection. Both protocols of H2S 
postconditioning produced significant and similar cardioprotective effects on both 
cardiodynamic performance and myocardial infarction. These data suggest that 
interference of the early phase of reperfusion may produce strong cardioprotection 
against ischemic injury. Interestingly, the signaling mechanisms for the cardioprotection 
induced by the two protocols are not totally same. In addition to the common signaling 
mechanisms that both SPostC and SPostC2 stimulated Akt and PKCδ, each of them 
activated different individual signaling mechanisms. SPostC, the six intermittent 
administrations of H2S, was able to activate PKCα and PKCε, whereas SPostC2, 
continuous infusion of H2S for two min, initiated eNOS phosphorylation. These data 
suggest that the signaling mechanisms for postconditioning are complicated. Properly 
manipulation of the early phase of postconditioning may have important clinical 
implications.  
Over the decades, Akt pathway has become such a target due to its role as a 
signaling pathway where modulation of substrates prevents apoptosis. Akt functions as 
a survival kinase by phosphorylating a number of apoptosis-regulatory molecules such 
as BAD, forkhead transcription factors, caspase 9, and IkB kinase to regulate NF-kB 
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and GSK-3β (Mullonkal and Toledo-Pereyra, 2007). Notably, several studies have 
suggested that H2S may protect hearts from myocytes apoptosis (Hu et al., 2007c; 
Sodha et al., 2008), which could be correlated with our data that SPostC/SPostC2-
induced Akt activation. Therefore, the anti-apoptotic effect of H2S may contribute 
significantly to the cardioprotection exerted by SPostC/SPostC2 through Akt activation.  
Although in the present study I demonstrated that the cardioprotection induced 
by IPostC and SPostC involves Akt, eNOS and PKC pathways, the effectors of this 
postconditioning is still unknown. There is a general trend which suggests that 
mitochondrial KATP channel opening is one of the downstream effectors of IPostC 
(Mykytenko, 2005; Penna et al., 2007; Yang et al., 2004b). Previous studies have shown 
that blockade of KATP channels attenuated the protective effect of H2S preconditioning 
(Bian et al., 2006; Pan et al., 2006). More importantly, H2S was shown to be a direct 
KATP channel opener in vascular smooth muscle cells (Tang et al., 2005; Zhao et al., 
2001) and insulin secreting cells (Yang et al., 2005a). As such, the opening of KATP 
channels by H2S could possibly serve as one of the downstream effectors of H2S 
postconditioning. In addition, H2S has been shown to scavenge H2O2 in vitro (Geng et 
al., 2004a) therefore to protect neuronal cells from oxidative stress (Kimura and 
Kimura, 2004) and hearts from ischemia injuries (Geng et al., 2004a). Moreover, H2S 
has been shown to attenuates myocardial ischemia-reperfusion injury by preserving 
mitochondrial function (Elrod et al., 2007). In this context, the large amount of release 
H2S during IPostC may protect the heart from ischemia-reperfusion injury partly via 
inhibiting reactive oxygen species (ROS) generation (Sun et al., 2005), oxidant 
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mediated injury (Kin et al., 2004) and preservation of mitochondrial function (Elrod et 
al., 2007), all of which may also contribute to the effects of SPostC and SPostC2.  
In the current study, I used constant flow in our isolated heart model. At the 
beginning of reperfusion, coronary perfusion pressure increases less and slower in the 
constant–flow model as compared to constant–pressure model which reaches the 
selected/baseline value immediately (Penna et al., 2006). Unlike the constant pressure 
model, this prevents the reactive hyperemia due to sudden increase in pressure that 
occurs during reperfusion after the global ischemia. This would result in lower 
production of ROS and eventually resulted in less myocardial injuries (Sato et al., 
1997).  Indeed, the IPostC showed greater infarct-sparing effect in the constant-flow 
than in the constant-pressure model (Penna et al., 2006). Therefore, it would be better to 
test the involvement of ROS in the cardioprotection of H2S postconditioning using a 
constant-flow isolated heart model. 
I previously demonstrated that H2S may induce intracellular acidification in 
aorta smooth muscle cells (Lee et al., 2007). However, the intracellular pH regulatory 
effect may not play a major role in the cardioprotection induced by SPostC and SPostC2 
in the current study. This is because H2S induced intracellular acidification can only be 
achieved after administration of H2S for 5 min (Lee et al., 2007), which is much longer 
than the perfusion period of H2S used in the current study.  
It was demonstrated in Chapter 3 that endogenous H2S may participate ischemic 
preconditioning (IP) as application of PAG could essentially abrogate the protective 
effect of IPC. This is alike to the observation obtained in the case of IPostC. Similarly, 
exogenous H2S could serve as a pharmacological agent to induce IP (H2S-
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preconditioning) in both immediate (Bian et al., 2006) and delayed (Pan et al., 2006; 
Pan et al., 2007) window. The mechanisms involved have been intensively studied by 
several groups, including opening of sarcolemmal KATP channels, PKCs (δ-, α-, ε-
isoforms) activation, NOS activation (Bian et al., 2006; Pan et al., 2007), heat shock 
protein 71 (Bliksoen et al., 2008), ERK and PI3K/Akt pathways (Hu et al., 2008b). In 
the present study, I showed that PKC, PI3K/Akt, and eNOS are involved in H2S-
postconditioning, indicating that the mechanisms are highly similar to those stimulated 
by H2S-preconditioning. 
 Taken together, it was demonstrated for the first time that endogenous H2S plays 
an important role in modulating the cardioprotective effects of IPostC. Postconditioning 
with exogenous H2S is able to resume heart contractile functions to a similar extend as 
those produced by IPostC probably via activation of PKC and/or Akt/eNOS pathway. 
The effect of H2S postconditioning against ischemia-reperfusion injury has provided a 
firm ground to support H2S as a cardioprotective gasotransmitter.  
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Chapter 5   Hydrogen sulfide interacts with nitric oxide 
in the heart - Possible Involvement of nitroxyl 
5.1. Introduction 
In previous chapter, I found that H2S increased nitric oxide (NO) production via 
activation of endothelial NO synthase (eNOS). It would be interesting to find out what 
is the physiological function of this increased NO together with H2S administration.  
 I was also interested to examine the interaction between H2S and NO in 
biological system. Several reports demonstrated that H2S and NO may influence the 
production of each other (Li et al., 2009; Minamishima et al., 2009; Pan et al., 2006; 
Yong et al., 2008a; Zhao et al., 2001). In addition, Whiteman et al proposed that H2S 
may interact with NO to form an unidentified nitrosothiol moiety, which may regulate 
the physiological effects of both NO and H2S (Whiteman et al., 2006). 
Bearing the strong reducing capability of H2S (Szabo, 2007; Wang, 2002; 
Warenycia et al., 1989) in mind, it is possible that H2S may putatively reduce NO, with 
or without the action of enzymes or other biological substances, to form nitroxyl 
(HNO), the one-electron reduced and protonated sibling of NO. The cardiovascular 
functions of HNO have been recently studied. It induces vasodilation and enhances 
heart contractility (Irvine et al., 2008). The potent-positive inotropic effect of HNO 
appears to be unique among all nitrogen oxides and its property of being unrelated to 
beta-adrenergic signaling renders HNO to be a tremendously potential pharmacological 
treatment for heart failure and other cardiovascular ailments. However, HNO has not 
yet been evidently shown to be endogenously biosynthesized as a signalling molecule. 
It also remains unclear whether HNO formation can have a specific physiological 
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function. In the current study, I aim to elucidate the function of the interaction between 
H2S and NO, and to explore the plausibility of these two biological gases being a source 
of endogenous HNO production in the heart.  
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5.2. Materials and methods 
5.2.1. Methods 
Isolation of adult rat cardiomyocytes, measurement of intracellular calcium, contractile 
and relaxation function of myocytes have been described in the Materials and Methods 
in Chapter 2 and 4 respectively.  
5.2.2. Drugs and chemicals 
Type 1 collagenase, protease XIV, isoproterenol (ISO), sodium hydrogen sulfide 
(NaHS), sodium nitroprusside dihydrate (SNP), L-arginine (L-arg), diethylamine 
NONOate sodium salt hydrate (DEA/NO), Rp-Adenosine 3′,5′-cyclic 
monophosphorothioate triethylammonium salt hydrate (Rp-cAMP), 8-(4-
Chlorophenylthio)-guanosine 3′,5′-cyclic monophosphorothioate, Rp Isomer 
triethylammonium salt (Rp-cGMP), N-acetyl-cysteine, L-cysteine, glutathione (GSH), 
and caffeine were purchased from Sigma Aldrich, Singapore. Fura-2 was purchased 
from Molecular Probes Inc. USA. Angeli’s salt was purchased from Cayman Chemical, 
USA. All are dissolved in water, with the exception of Fura-2 (in DMSO) and Angeli’s 
salt (in 0.01M NaOH). 
5.2.3. Statistical Analysis 
Values presented are mean ± standard error of mean. SPSS for Windows (11.5.0, LEAD 
technologies, USA) was used to perform the analysis. One-way analysis of variance 
(ANOVA) was used to determine the difference among groups. A post hoc Bonferroni 
analysis was used to determine the significant differences between the groups. The 




5.3.1. Effect of NO increasing agents on cardiomyocyte  contraction in the 
presence or absence of NaHS 
Freshly isolated adult rat mycocytes were exposed to 50 µM of each of the following 
drugs: NaHS (an H2S donor), L-arg (a substrate of NOS to produce NO), SNP (an NO 
donor) or DEA/NO (an NO donor). As shown in Figure 5-1A-B, all the three NO 
increasing agents (L-arg, SNP and DEA/NO) significantly decreased the twitch 
amplitudes of myocytes. Surprisingly, when given together with NaHS, which itself had 
no significant effect on myocyte contraction, these three NO increasing agents produced 
positive, instead of negative, inotropic effect. These data imply that an interaction 
between NO and H2S may exist.  
Since the three NO increasing agents produced similar effects, and the fact that 
SNP allows better definition of the NO concentration than L-arg and is much more 
stable than DEA/NO in aqueous solution(Kowaluk et al., 1992), SNP was chosen for 
the subsequent experiments. The concentration-dependent effect of the mixture of SNP 
and NaHS (SNP+NaHS) was observed. As shown in Figure 5-1C, SNP+NaHS 
(concentration ratio: 1:1) increased myocytes contractility when each concentration was 
at a range from 50-200 µM. The maximum effect (~150% augmentation) was observed 
when each concentration was at 100 µM. To avoid possible toxic effect, SNP+NaHS at 
50:50 μM was chosen in the subsequent experiments.  
Since it was reported that 1 µM SNAP significantly increased cell 
shortening,(Vila-Petroff et al., 1999) it is interesting to examine whether NaHS+SNP at 
50:1 µM could produce stronger effect than they do at 50:50 µM. As shown in Figure 5-
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1D, SNP at 1 µM increased myocyte contractility by ~ 28%, but this effect was 
abolished by co-application with 50 µM NaHS. This data suggest that the concentration 
ratio of SNP:NaHS is critical to exert the positive inotropic effect.    
I further observed whether SNP+NaHS can change the velocities of myocyte 
contraction and relaxation. As shown in Figure 5-1E, NaS also reversed the maximal 
velocities of cell shortening (-dL/dt) and cell relaxing (+dL/dt) from negative value 
caused by SNP alone to the positive values (Figure 5-1E). These data suggest that 











Figure 5-1 Effect of NO increasing agents on myocyte contractility in the presence or absence of 
NaHS in electrically-stimulated rat ventricular myocytes. (A) Representative tracings of cell 
shortening in ventricular myocytes treated with L-arginine (L-arg), SNP or DEA/NO in the presence or 
absence of NaHS. (B) Group data showing that all the three NO increasing agents (L-arg, SNP, and 
DEA/NO), which themselves alone decreased myocyte contraction, produced positive inotropic effects in 
the presence of NaHS. (C) Concentration-dependent response of NaHS+SNP (concentration ratio at 1:1, 
each at 10 ~ 200 μM) on cell shortening. (D) Effect of SNP (1 μM) in the presence or absence of NaHS 
(50 μM). (E) Effect of NaHS and SNP on the velocity of cell shortening (-dL/dt) and relaxing (+dL/dt). 




5.3.2. Effect of SNP on intracellular calcium transients in the electrically-
induced (EI) ventricular myocytes in the presence or absence of NaHS 
To determine the effect of NO and H2S donors on calcium handling, I observed the 
effect of H2S on the amplitudes of EI-[Ca2+]i transients. As shown in Figure 5-2A-C, 
NaHS had no significant effect, but SNP decreased the amplitudes of EI-[Ca2+]i 
transients. However, SNP+NaHS significantly augmented the amplitudes of calcium 
transients (Figure 5-2A-C). I also analyzed the decay time constant, Tau. As shown in 
Figure 5-2D, NaHS+SNP evidently shortened the decay time when compared to 
control, NaHS or SNP alone, suggesting that NaHS+SNP may induce a faster calcium 
removal from cytosol via increasing the activity of either sarco/endoplasmic reticulum 















Figure 5-2 Effect of SNP on EI-[Ca2+]i transients in the presence or absence of NaHS in the rat 
ventricular myocytes. (A-B) Representative tracings (A) and group data (B) showing that NaHS+SNP 
increased, whereas SNP alone decreased the amplitudes of EI-[Ca2+]i transients. (C-D) Representative 
tracings (C) and group data (D) showing that NaHS+SNP increased the velocity of calcium decay as 
shown by the decreased decay time. Mean±SEM, n = 6-9, *p<0.05, ** p<0.01 vs control group. 
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5.3.3. Effect of SNP on resting calcium and caffeine-induced calcium 
transients in the ventricular myocytes in the presence or absence of NaHS 
Figure 5-3A and 5-3B show that SNP (50 μM) significantly decreased the calcium level 
at resting status. However, SNP markedly increased the resting calcium level in the 
presence of NaHS, which itself alone had no significant effect on calcium level. I also 
found that the effect of NaHS+SNP on resting calcium was dependent on intracellular 
store, as pretreated the myocytes with thapsigargin (2 μM, 1 hr) or ryanodine (15 μM, 1 
hr) essentially abolished the effect of NaHS+SNP. (Figure 5-3C & 3D)  Interestingly, 
SNP+NaHS failed to affect the amplitude and the decay velocity of caffeine-induced 
calcium transients (Figure 5-3E-H). These data suggest that the inotropy and lusitropy 
of SNP+NaHS may be related to ryanodine receptor and SERCA, but not via altering 




Figure 5-3 Effect of SNP on resting [Ca2+]i and caffeine-induced [Ca2+]i transients in the rat 
ventricular myocytes. (A) Representative tracings of resting [Ca2+]i in myocytes treated with NaHS, SNP 
or SNP+NaHS. (B) Group data showing that SNP+NaHS increased resting [Ca2+]i level when it was 
measured 1000 s after drug treatment. (C-D) Representative tracings (C) and group data (D) showing that 
the effect of NaHS+SNP was sensitive to ryanodine and thapsigargin. (E-F) Representative tracings of 
caffeine-induced [Ca2+]i transients in the absence (E) or presence (F) of SNP+NaHS. (G-H) Group data 
showing that SNP+NaHS treatment had no significant effect on both amplitudes and decay of caffeine-




Effect of HNO on cell contractility, EI-[Ca2+]i transients and resting calcium in isolated 
cardiomyocytes 
The above data suggest a new compound may be formed upon mixing NO and H2S. To 
examine the involvement of HNO, Angeli’s salt (AS), an HNO donor, was used. As 
shown in Figure 5-4, AS concentration-dependently augmented the amplitudes of both 
cell shortening (Figure 5-4A & 5-4D) and [Ca2+]i transients in electrically stimulated 
ventricular myocytes (Figure 5-4B, C & F). The effect of AS was completely abolished 
when the cells were pre-incubated with HNO scavenger N-acetyl-cysteine (NAC, 1 
mM)(Favaloro and Kemp-Harper, 2007), L-cysteine (L-cys, 1 mM)(Irvine et al., 2008) 
and glutathione (GSH, 1 mM)(Tocchetti et al., 2007) (Figure 5-4E & G). This is in line 
with several previous reports(Favaloro and Kemp-Harper, 2007; Irvine et al., 2007; 
Paolocci et al., 2001; Tocchetti et al., 2007). In addition, I also found that AS at 500 μM 
increased resting calcium by ~10%, which was abolished by pretreatment of the cells 
with thapsigargin (2 μM, 1 hr) or ryanodine (15 μM, 1 hr) (Figure 5-4H & I). These data 






Figure 5-4  Effect of AS on cell shortening in electrically-stimulated rat ventricular myocytes 
in the absence or presence of HNO scavengers. (A-C) Representative tracings of myocyte shortening 
(A) and [Ca2+]i transients (B-C) in the presence or absence of AS. (D-E) Concentration-dependent effect 
of AS on cell shortening (D) and [Ca2+]i transients (E). (F-G) HNO scavengers (NAC, L-cys and GSH) 
abolished the effect of AS (500 μM) on cell shortening (F) and [Ca2+]i transients (G). (H-I) Representative 
tracings and group data showing that the effect of AS was sensitive to ryanodine (Ryan) and thapsigargin 





5.3.4. Effect of NO+H2S involves HNO 
To test the hypothesis that the effect of NO+H2S is due to the formation of HNO, I 
incubated the cells with the different HNO scavengers 10 min prior to the application of 
SNP+NaHS. Our data showed that all the three scavengers (NAC, L-csy and GSH) 
abolished the effect of SNP+NaHS on both cell shortening (Figure 5-5A & D) and 
[Ca2+]i transients (Figure 5-5C & E). Similarly, addition of NAC (1 mM) 20 min after 
administration of SNP+NaHS reversed the positive inotropic effect of SNP+NaHS 










Figure 5-5 Effect of NaHS+SNP on myocyte contraction and EI-[Ca2+]i transients in the 
presence or absence of HNO scavengers. (A & C) Representative tracings of myocytes cell shortening 
(A) and [Ca2+]i transients (C) in the control and NaHS+SNP treatment groups in the cells pre-incubated 
with or without a HNO scavenger (NAC, L-cys or GSH). (B) Representative tracing of continuous 
recording of myocytes cell shortening showing that NAC reversed the positive inotropic effect of 
NaHS+SNP. (D-E) The effects of NaHS+SNP on cell shortening (D) and [Ca2+]i transients (E) were 
abolished by pretreatment with HNO scavengers. Mean±SEM, n = 8-12, *p<0.05 vs control, #p<0.05, 
##p<0.01 vs NaHS+SNP group. 
  
120
5.3.5. The positive inotropic effect of H2S+NO is independent of cAMP/PKA 
and cGMP/PKG pathways 
cAMP is an important second messenger to regulate heart contractility. To examine 
whether the effect of H2S+NO involves cAMP, I pretreated the ventricular myocytes 
with Rp-cAMP (100 μM), a membrane permeable PKA inhibitor, 5 min before the 
addition of NaHS+SNP.  Figure 5-6A shows that Rp-cAMP significantly attenuated the 
positive inotropic effect of ISO, but had no effect on that of SNP+NaHS. Similarly, Rp-
cGMP (10 μM, a PKG inhibitor) abolished the negative inotropic effect of SNP (500 
μM), but failed to affect the positive effect of SNP+NaHS (Figure 5-6B). These data 
suggest that the effect of H2S+NO is also independent of cGMP/PKG pathway.  
Both ISO (10 nM) and SNP+NaHS induced positive inotropic effects (34.6 ± 8.6% and 
26.6 ± 1.9%, respectively, Figure 5-6C). Of note, co-application of ISO and SNP+NaHS 
produced even stronger contraction (62.4 ± 6.4%, Figure 5-6C). The above data suggest 
that the action of H2S+NO may be in parallel with the β-adrenergic pathway, and 



































Figure 5-6 Effect of NaHS+SNP on myocyte contraction upon blockade of PKA or 
PKG or stimulation of β-adrenoceptor. (A) Blockade of PKA with Rp-cAMP significantly 
attenuated the effect of ISO, but not that of NaHS+SNP, on myocyte contraction. n = 8-12. (B) 
Blockade of PKG with Rp-cGMP significantly attenuated the effect of SNP (500 μM), but that of 
NaHS+SNP, on myocyte contractility. n = 6-11. (C) Additive effect of SNP+NaHS and ISO on 
myocyte contraction, n= 11-15. Mean±SEM, *p<0.05, **p<0.01 vs control; #p<0.05 vs ISO or 





The main objective of this study is to investigate the interaction between H2S and NO in 
the heart.  By measuring myocyte contractility and EI-[Ca2+]i transients, I found that 
NaHS at 50 μM had negligible effect, whereas NO donors produced negative inotropic 
effect in the cardiomyocytes. This is consistent with the previous reports (Flesch et al., 
1997; Miranda et al., 2005; Sun et al., 2008; Tatsumi et al., 2000; Yong et al., 2008a; 
Yong et al., 2008b). However, unexpectedly, when these two kinds of donors mixed 
together, I observed a marked increase in the resting calcium, EI-[Ca2+]i transients and 
myocyte contractility accompanied by augmented velocities of myocyte contraction and 
relaxation. Since both stimulating endogenous NO production with L-arginine and 
exogenous application of NO donors produced similar effects, the possibility that the 
effect merely resulted from chemical reaction of two donors can be excluded. The 
completely opposite effects of NaHS+SNP as compared to that caused by each 
individual donor led us to hypothesize that a new compound is formed from the 
interaction between H2S and NO.  
The importance of the reducing capability of H2S (Szabo, 2007; Wang, 2002; 
Warenycia et al., 1989) and the structural property of HNO with one-electron reduced 
and protonated sibling of NO prompted us to postulate HNO as one of the most likely 
candidates of the new compound formed during the interaction of H2S with NO. To test 
this hypothesis, I determined the effect of AS, an HNO donor, and different types of 
thiols (NAC, L-cys and GSH), which were shown to be effective HNO scavenger 
(Irvine et al., 2008; Paolocci et al., 2007), on myocyte function. I found that AS 
mimicked the effect of SNP+NaHS, whereas the thiols abolished the effects of both AS 
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and NaHS+SNP. Our data suggest that the cardiac effect of NaHS+SNP may involve 
HNO. 
Previous studies demonstrated that HNO donors improve function in the failing 
heart via β-adrenoceptor independent pathway(Paolocci et al., 2003; Paolocci et al., 
2001). Furthermore, it was reported that inhibition of cAMP/PKA and cGMP/PKG had 
no impact on AS inotropy (Tocchetti et al., 2007). Similarly, in the present study I 
found that the action of NaHS+SNP was independent of cAMP/PKA and cGMP/PKG 
pathways. In addition, HNO and β-adrenoceptor stimulation produced additive positive 
inotropic effects whereas both NO donors (Massion et al., 2005; Tocchetti et al., 2007) 
and NaHS (Yong et al., 2008b) negatively modulate β-adrenergic stimulation. These 
features of NaHS+SNP have laid further supports to the hypothesis that HNO may 
mediate the effect of NaHS and SNP.  
HNO enhances fractional calcium release from SR via increasing the open 
probability of ryadonie receptors (Tocchetti et al., 2007). This explains why 
SNP+NaHS increased the amplitudes of myocyte contraction and [Ca2+]i transients 
caused by electrical stimulation. Our data that the elevated resting [Ca2+]i was abolished 
by ryanodine further confirm that SNP+NaHS  may also act on ryanodine receptors.  
HNO also activates SERCA through S-glutathiolation at cysteine 674 (Lancel et 
al., 2009). This is supported by our data that SNP+NaHS accelerated the decay rate of 
EI-[Ca2+]i. Interestingly,  HNO did not affect the total calcium uptake to SR, although it 
significantly increased calcium uptake velocity (Tocchetti et al., 2007). This helps to 
explain why SNP+NaHS improved SERCA activity without altering SR calcium load.  
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So how is HNO produced in the biological system? H2S may interact with NO 
via direct or indirect ways. As a strong reducing agent, H2S might interact directly with 
NO to form HNO. HNO may also be generated via reduction of NO by elements of the 
electron transport system in mitochondria (Zhao et al., 1995), ubiquinol(Poderoso et al., 
1999), manganese superoxide dismutase (Niketic et al., 1999), and xanthine oxidase 
(Saleem and Ohshima, 2004). In addition, it was also demonstrated that HNO can be 
generated from NOS especially in the absence of tetrahydrobiopterin (Fukuto et al., 
2005a), or after oxidation of the NOS intermediates, N-hydroxy-L-arginine(Fukuto et 
al., 2005a; Irvine et al., 2008) and hydroxylamine (Donzelli et al., 2008). Notably, 
several other reports also demonstrated that H2S may enhance eNOS phosphorylation 
(Minamishima et al., 2009; Pan et al., 2006; Yong et al., 2008a). It is therefore possible 
that HNO can be generated indirectly from H2S-stimulated NOS activation. 
Furthermore, the reaction of S-nitrosothiol with excess thiols may also result in release 
of HNO. (Paolocci et al., 2007; Spencer et al., 2003) Whiteman et al. reported that a 
biologically inactive nitrosothiol may be chemically formed from the reaction between 
H2S and NO (Whiteman et al., 2006). These findings suggest that the intermediate 
substance, nitrosothiol, may further react with thiols to form HNO (Minamishima et al., 
2009; Pan et al., 2006; Yong et al., 2008a).  
we and other groups have demonstrated that eNOS or nNOS activation is 
important for H2S to exert cardioprotective effects. For instances, H2S may be used to 
induce pharmacological pre- (Pan et al., 2006) and post-conditioning(Yong et al., 
2008a) to protect the heart against ischemia-reperfusion injury via several pathways 
including eNOS activation. Minamishima et al. also found that administration of H2S 
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donor markedly improves myocardial function and survival after cardiac arrest in mice, 
but the protective effects of H2S was abrogated in eNOS deficient mice (Minamishima 
et al., 2009). These findings suggest that NO plays an important role in the 
cardioprotection conferred by H2S in different pathological models. Given the positive 
inotropic effect of H2S+NO, generation of HNO in the reaction of these two gases may 
be important to resume the depressed cardiac function back to normal after cardiac 
arrest or ischemia-reperfusion insult. 
The biological effect and significance of HNO need to be confirmed by 
detection of HNO in the interaction of H2S and NO. Unfortunately, there is no specific 
and sensitive detection method for HNO measurement. The current indirect detection 
methods for HNO, including measurement of N2O, reductive nitroxylation of oxidized 
metal complexes and detection of reaction products of HNO with thiols, cannot be 
applied to intact cells and fail to detect low level of HNO production (Irvine et al., 
2008). In addition, the high reactivity of both HNO and NO, particularly self 
consumption by dimerization (Fukuto et al., 2005b), creates extra challenges for HNO 
detection. The lack of a specific HNO measurement method hampered us in 
demonstrating the conclusive evidence that HNO is the playmaker of the inotropic 
effect induced by H2S+NO. A specific method needs to be developed to test whether 
HNO is produced by the reaction between H2S and NO. 
Another interesting question to be asked is that whether sufficient H2S and NO 
can be produced in the human body to generate HNO during the physiological situation.  
The rate of H2S production in tissue homogenates has been reported to be about 1 – 10 
pmoles per second per mg protein, resulting in low micromolar extracellular 
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concentrations (Doeller et al., 2005). Previous study showed that both rat and human 
plasma contain approximately 50 μM of H2S (Zhao et al., 2001), which were recently 
challenged by Whitfield et al who found that the free H2S gas was essentially 
undetectable (<100 nM total sulfide) in all animals (Whitfield et al., 2008). On the other 
hand, mammalian plasma nitrite level, which is often used to indicate the NO level due 
to its relatively stable characteristic, was shown to range from ~100 nM to 1μM (Rassaf 
et al., 2003). In this context, it is possible that nanomolar of HNO may be constitutively 
formed within mammalian system. Mice with genetic deletions of both eNOS and 
nNOS together with CSE will be crucial to find out whether this nanomolar 
concentration of HNO is enough to exert any significant physiological effect in the 
cellular microenvironment. This will be of both scientific and clinical importance, as the 
finding may improve the understanding of cardiac contractile mechanisms.   
Perhaps HNO may play a more important role during pathological situations. 
For instance during inflammation, iNOS is induced and activated in myocardium. This 
may lead to large production of cytosolic NO. Similarly, it has also been reported that 
H2S level is markedly higher during inflammation as compared to physiological level 
(Li et al., 2005; Mok et al., 2004). This may imply that during inflammation, large 
amounts of NO and H2S can be produced and lead to over-production of HNO which 
may increase [Ca2+]i and therefore induces arrhythmias. As such, our study may be 
helpful to reveal a novel therapeutic strategy to treat inflammation-induced arrhythmias.  
There are several limitations in this study. The hypothesis that HNO is generated 
after mixing H2S and NO is no conclusively proven with direct HNO measurement, thus 
one should not rule out the possibility that the resultant inotropic effect of H2S+NO may 
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be due to the interaction of the two signalling pathways stimulated by H2S and NO 
individually. Although the hypothesis that the generation of HNO by H2S+NO is 
supported by the data showing the effects of H2S+NO can be abolished by thiols, we 
should also bear in mind that the thiols used in this study are not HNO-specific 
scavengers because they are also able to scavenge reactive oxygen species.  
In conclusion, our study shows that H2S may interact with NO to form a new 
compound (probably HNO) which produces positive inotropic and lusitropic effect. Our 
study may add another dimension on the study of gasotransmitters, and potentially 
change the therapeutic strategy to treat cardiovascular diseases. 
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Chapter 6   General Discussion 
 
This thesis first investigated the physiological, pathological and therapeutic roles of H2S 
in normal or ischemic heart followed by examining the biological and physical 
interaction of H2S with NO, another important gaseous mediator. It was found that H2S 
regulates β-adrenergic function in the heart and mediates the cardioprotection caused by 
ischemic preconditioning and postconditioning. By focusing on the effect of H2S on 
ECG and contractile function of the isolated heart, as well as cellular calcium handling 
and contractility in the models of I/R and beta-adrenergic stimulation, our studies 
evidently demonstrated that H2S may serve as pharmacological preconditioning & 
postconditioning agent, and produces potent cardioprotective effects which translated 
into decreased cell death, prevention of intracellular calcium overload, preserved 
contractile function, restraint of infarct size, as well as reduction of both severity and 
duration of ventricular arrhythmias. Further investigations, focusing on the role of H2S 
on intracellular NO production, lead to a novel understanding of the complicated 
functions exerted by these two gases, which may potentially change the therapeutic 
strategy to treat cardiovascular diseases.  
 Using isolated rat cardiomyocytes, I identified several essential signaling 
components and intracellular events mediating the protection afforded by H2S 
treatment. With free passage through the plasma membrane, H2S preconditioning exerts 
cardioprotective effect via directly or indirectly opening of sarcolemmal KATP channel, 
as well as activation of different PKC and NOS isoforms. Via some unclear 
mechanisms, H2S post conditioning activates Akt/eNOS pathways and also translocates 
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different PKC isoforms (PKC-α, -δ, and –ε) from cytosol to membrane fraction of the 
cells where calcium handling proteins such as SERCA and NCX are located. In 
addition, H2S treatment effectively antagonizes β-adrenergic stimulation via inhibiting 
adenylyl cyclase activity. The effect of H2S on PKC activation, which results in faster 
clearing of cytosolic calcium back to SR or extracellular compartment (Pan et al., 
2007), together with its effect to reduce cAMP production, which causes less calcium-
induced calcium release from SR, make H2S a powerful therapeutic agent to ameliorate 
calcium overload in myocytes. This beneficial effect of H2S may hence contribute to 
reduced apoptosis/necrosis and hypercontracture of the myocytes, which ultimately lead 






















Figure 6-1 H2S negatively regulates β-adrenergic system via inhibiting adenyly l cyclase activity.  
Gs, stimulatory G protein; PDE, phosphodiesterase; RyR, Ryanodine receptor; PKA, protein kinase A; 




However, I also bear in mind that the whole scenario of the signal transduction could be 
much more complicated. The signaling pathway outlined above is by no means the only 
route for H2S treatment to exert its functions. Of note, our and other groups have shown 
that the cardioprotective effect of H2S was significantly contributed by NOS activation 
(Pan et al., 2006) (Minamishima et al., 2009), in line with these studies, I found that 
H2S enhanced eNOS phosphorylation and intracellular NO production in 
cardiomyocytes, which may in turn react with H2S and form a new compound 
endogenously. With the potential involvement of H2S, NO and their reaction product, 
which may possess different functions via acting on variety of pathways individually, it 
is more like a signal network than single pathways which transforms the extracellular 
stimulus of H2S into the final protection.  
Intriguingly, during the process of investigating the effect of H2S on NO 
production, I found that the resultant effect of H2S+NO is completely opposite to its 
parental gas respectively (Table 7-1). By comparing the effect of H2S+NO and HNO on 
cardiomyocytes functions (Table 7-2), I are convinced that H2S+NO may form HNO 
with the help of, for instance, elements of the electron transport system in mitochondria 
(Clarkson et al., 1995; Zhao et al., 1995).   The hypothesis that mixing H2S with NO 
may form HNO, would fill up a major knowledge gap in our understanding on why NO, 
which showed a positive inotropic effect on myocytes and hearts in low concentration, 
become negative inotropy at high concentrations (Massion et al., 2003). These 
intriguing observations are not hard to be explained when I consider the existence of 
basal H2S production and the interesting observations may be due to the formation of 
HNO in the experimental system.  
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Additionally, the understanding of the potential formation of HNO from the 
reaction between H2S and NO may be important when both of the gaseous transmitters 
are significantly up-regulated in some pathological conditions, for examples during 
inflammation. On the other hand, mixture of H2S and NO could be an effective 
treatment to heart failure, since the reaction product of H2S and NO may improve heart 
functions via cAMP-independent pathway. In general, my study has highlighted the 





  Biological effect NO+H2S HNO 
1 Inotropy Positive Positive 
2 intracellular calcium Increase Increase 
3 Sensitive to thiols? Yes Yes 
4 SERCA activity Increase Increase 
5 NCX activity No change No change 
6 SR calcium load No change No change 
7 regulation of β-adrenergic function Additive, parallel Additive, parallel 
 
Ever since the first discovery of endogenously produced H2S and the expression of 
the enzymes responsible for its production in the brain, vasculature, liver and heart, a 
large amount of works have been done to examine the physiological and pathological 
roles of this new emerging gasotransmitter. However, the majority of the evidence was 
  Biological effect NO H2S NO+H2S 
1 Inotropy negative negative Positive 
2 intracellular calcium decrease no change/decrease Increase 
3 Sensitive to thiols? No probably No Yes 
4 regulation of β-adrenergic function Negative Negative Additive 
Table 7-1 Comparison of the biological effects of NO, H2S and NO+H2S on the 
cardiomyocytes 
Table 7-2 Comparison of the effects of NO, H2S and NO+H2S on the calcium handling 
machinery in cardiomyocytes 
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based on the exogenous administration of H2S donor and/or non-specific CSE or CBS 
inhibitors, which render the physiological role of H2S in these mammalian systems 
inconclusive and controversial. As such, study on mice with genetic deletion of H2S -
producing enzymes is of importance. Recently, Yang et al successfully developed this 
kind of genetically manipulated mice, and further reported that pronounced 
hypertension and diminished endothelium-dependent vasorelaxation were observed in 
CSE knock out mice (Yang et al., 2008). This group of researchers found that the 
relaxation induced by methacholine, an agonist of muscarinic receptor, in the PE-
precontracted mesenteric arteries was significantly impaired in CSE-/- mice, suggesting 
that H2S functions as an endothelial cell-derived relaxing factor (EDRF) in this vascular 
bed (Yang et al., 2008). This is in line with the reports mentioned previously, and 
provides direct evidence that H2S is a physiologic vasodilator and regulator of blood 
pressure. It will be of scientifically significance shall more experiments be done on this 
CSE knock out mice to confirm the observations in my studies. 
To date, simple sulfide salts, most commonly NaHS, have been the H2S-releasing 
drugs used in most of the study published around the world, including our present study. 
NaHS is known to release H2S instantaneously in aqueous solution. Because the release 
of endogenous H2S from cells is likely to occur in lesser amounts and at a much slower 
rate, NaHS may not mimic the biological effects of naturally produced H2S. Yet, based 
on findings in the current study, preconditioning or postconditioning with NaHS is able 
to protection against cardiac ischemia/reperfusion injury, even if it only transiently 
increases the circulating H2S levels. When compared to slow H2S-releasing compounds 
like GYY4137 (Li et al., 2008) and S-declofenac (Li et al., 2007), NaHS, being a 
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relatively pure H2S-donor which only releases Na+ and HS- ions, offer an easy 
definition of H2S concentration when it is used in different experiments to delineate the 
biological functions of H2S. 
However, development of organic compounds that slowly release free H2S over 
extended periods of time is necessary, because a slower and lower H2S concentration 
release to patients is essential in terms of sustained therapeutic effect as well as reduced 
potential toxicity and side effects of H2S. Recently there has been increasing interest 
looking into the feasibility of reducing the side effects of certain drugs by adding H2S-
releasing moiety on the compounds. Administration of H2S donors could prevent the 
decrease in gastric blood flow induced by nonsteroidal anti-inflammatory drugs 
(NSAIDs), as well as attenuating NSAID-induced leukocyte adherence (Fiorucci et al., 
2006; Ortiz et al., 2001). Indeed, it was reported that a H2S-releasing derivative of 
diclofenac, a kind of NSAID, was substantially better tolerated, in terms of gastric 
damage, than the parent drugs.(Li et al., 2007; Wallace et al., 2007)  
Since long period of H2S treatment has shown therapeutic effects, drugs like 
GYY4137 or S-declofenac may be more useful for patients who have been discharged 
from hospital but require longer term medication to improve the prognosis of the related 
heart diseases. In addition, this kind of slow H2S-releasing drugs could be useful for 
treating patients who fail to access to H2S preconditioning or postconditioning before or 
after, respectively, occurrence of myocardial infarction. Bearing the cardioprotective 
effect in mind, H2S, on the other hand, may serve as a conjunctive treatment with some 
other treatments which may cause cardiac toxicity, for examples, anthracyclines, which 
are very effective antineoplastic agents with a broad antitumor spectrum (Huang et al., 
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2010). Production of H2S-releasing anthracylcines may greatly reduce the cardiac 
toxicity of the parental drug whereby increase the therapeutic window of this drug and 
render it more effective against tumors.   
Another potential area is the development of H2S as an inhaled gas or as a parenteral 
injectable. Inhaled NO has set a precedent for development of medical gases. NO was 
also first known as a toxic gas and is currently approved for use in infants with primary 
pulmonary hypertension (Hillier, 2003; Kinsella and Abman, 2005). However, the 
unpleasant odor of H2S may pose more problems for administration, which could 
necessitate the implementation of appropriate trapping systems to prevent from 
spreading into environment and exposure of medical personnel (Szabo, 2007). With 
enteral or parenteral formulations, odor would not create a problem, but manufacturing 
and formulation issues remains challenging compared with conventional chemical 
compound. In addition, animal safety data are still lacking with respect to parenteral or 
enteral administration of H2S. Although sulfide is an endogenous substance, all 
exogenous sulfide delivery systems would be required to pass stringent safety and 
efficacy tests in preclinical animal studies before progression into human studies. 
 
Of note, there are several limitations in the present study, namely: 
1) The effects of NaHS may not entirely represent the physiological roles of H2S in 
the tissues or cells since the formation of H2S by the enzymes is significantly 
slower than that produced by NaHS dissolving in the water. However, the 
protective roles of NaHS in different cardiac disease models should not be 
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denied since different groups of scientist have confirmed the cardioprotective 
effect of NaHS or other H2S-donors in various publications. 
2) The determination of H2S concentration in plasma or medium was performed by 
simple spectrophotomietric assay which involves some extreme conditions such 
as acidification of the samples. Although the absolute value of H2S levels 
presented in the thesis is questionable, the relative changes of the H2S levels in 
the samples after different treatments are still reliable.  
3) The formation of HNO by H2S+NO is not conclusively demonstrated because 
there is no specific and sensitive detection method for low amount of HNO 
generated in biological samples. More extensive chemical tests like high-
performance liquid chromatography and X-ray crystallography may be used to 
determine the structure of the reaction product of H2S+NO. 
To further elaborate the significance of the present study, the future experiments 
should focus on several important areas:  
1) Examine the effect of H2S+NO in the whole heart or whole animal, to confirm 
its physiological or pathological relevance. 
2) Confirm the chemical structure of the interaction product of H2S and NO which 
may facilitate the discovery of its specific scavengers and its target proteins or 
receptors. 
3) Improve the understanding of the physical, chemical and biological properties of 





Chapter 7  Conclusion 
 
The current study demonstrated that H2S negatively regulated β-adrenergic activation 
caused by ischemia/reperfusion stimulus. The cardioprotective effects were further 
proven by the findings of the involvement of endogenous H2S in the protection 
conferred by either ischemic pre- or post-conditioning, and the cardioprotection of 
pharmacological pre- or post-conditioning with H2S.  The protective effects of H2S may 
involve activation of several pathways including SarcKATP channel, PKC and 
Akt/eNOS. The present study illustrates the potential therapeutic role of H2S in the 
treatment of ischemic heart diseases. However, although the cardioprotective effects of 
H2S and NO have been consistently reproduced in vast amount of study, the clinical use 
of these gases should be applied with caution. This is because that the present 
desertation also demonstrated that H2S and NO may interact with each other to produce 
a novel substance, which possesses opposite biological functions to those caused by 
either H2S or NO alone. The discovery of this novel compound may be of importance in 
understanding the functional cross-talk between these two important gasotransmitters, 
and may potentially change the therapeutic strategies of treatment different 
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